

CITATION REPORT

List of articles citing

Updated clinical classification of pulmonary hypertension

DOI: 10.1016/j.jacc.2009.04.012

Journal of the American College of Cardiology, 2009,
54, S43-S54.

Source: <https://exaly.com/paper-pdf/46795102/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1813	Pulmonary vascular pathology. 661-710		2
1812	Expression of the Stp1 LMW-PTP and inhibition of protein CK2 display a cooperative effect on immunophilin Fpr3 tyrosine phosphorylation and <i>Saccharomyces cerevisiae</i> growth. 2004 , 61, 1176-84		10
1811	Computed axial tomography evidence of left atrial enlargement: a predictor of elevated pulmonary capillary wedge pressure in pulmonary hypertension. 2009 , 23		1
1810	Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. 2009 , 3, 269-87		35
1809	Present and Prospective Pharmacotherapies in Pulmonary Arterial Hypertension. 2009 , 1, CMT.S2108		
1808	Emphasizing the importance of the clinical classification for pulmonary hypertension. 2009 , 8, 267-268		5
1807	[Early diagnosis of connective tissue disease-related pulmonary hypertension]. 2009 , 32, 457-65		
1806	Management and Controversies in Pediatric Pulmonary Hypertension. 2009 , 22, 139-150		1
1805	Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. 2009 , 297, L1013-32		543
1804	PPARgamma activation: a potential treatment for pulmonary hypertension. 2009 , 1, 12ps14		60
1803	[Update: Current clinical developments in pulmonary hypertension]. 2009 , 134 Suppl 5, S160-3		0
1802	Pulmonary arterial hypertension in human immunodeficiency virus infection. 2009 , 121, 56-67		7
1801	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. 2009 , 18, 272-90		17
1800	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. 2009 , 27, 13-23		18
1799	Pulmonary arterial hypertension associated with congenital heart disease. 2009 , 27, 25-33		12
1798	Pulmonary venous hypertension or pulmonary hypertension due to left heart disease. 2009 , 27, 35-42		6
1797	[Pulmonary hypertension and heart failure: the role of pulmonary vasculature]. 2009 , 58, 304-9		2

- 1796 [Epidemiological aspects in chronic thromboembolic pulmonary hypertension]. **2009**, 45 Suppl 6, 2-5 1
- 1795 [Clinical and hemodynamic diagnosis in chronic thromboembolic pulmonary hypertension]. **2009**, 45 Suppl 6, 15-20 3
- 1794 Antikoagulation bei pulmonaler arterieller Hypertonie. **2009**, 6, 390-398 1
- 1793 Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. **2009**, 26, 813-25 75
- 1792 Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). **2009**, 30, 2493-537 2531
- 1791 Diagnosis and assessment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S55-S66 15.1 828
- 1790 Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. **2009**, 62, 1464.e1-1464.e58 1
- 1789 Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. **2009**, 9, 331-50 21
- 1788 [Specific clinical manifestations of pulmonary vascular diseases]. **2009**, 26, 1179-80
- 1787 Bosentan for chronic thromboembolic pulmonary hypertension. **2009**, 7, 1503-12 5
- 1786 [Eisenmenger syndrome. Role of rare diseases reference centers in the management of pulmonary hypertension in congenital heart diseases]. **2009**, 38 Suppl 1, 1S23-7
- 1785 Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. **2009**, 62, 1464.e1-1464.e58 3
- 1784 L'Hypertension artérielle pulmonaire et le cardiologue. **2009**, 2009, 6-8
- 1783 Algorithme diagnostique. Comment je raisonne devant une HTAP ?. **2009**, 1, 211-212
- 1782 Nouvelle classification de l'HTAP. **2009**, 1, 204-207
- 1781 Pulmonary hypertension in thoracic surgical patients. **2010**, 23, 25-33 18
- 1780 Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. **2010**, 22, 513-8 1
- 1779 Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. **2010**, 138, 1383-94 289

1778	Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. 2010 , 137, 205-295	84
1777	Clinical trials for pulmonary hypertension in the developing world: pulmonary vascular disease: the global perspective. 2010 , 137, 625-685	2
1776	Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. 2010 , 138, 1086-92	32
1775	Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. 2010 , 11, 719-24	22
1774	Nursing considerations in the care of patients with pulmonary hypertension. 2010 , 11, S74-8	1
1773	Anesthesia for patients with pulmonary hypertension. 2010 , 23, 411-6	72
1772	Intraoperative management of pulmonary hypertension and associated right heart failure. 2010 , 23, 49-56	26
1771	Current Opinion in Anaesthesiology. Current world literature. 2010 , 23, 116-20	
1770	Update on anaesthetic approach to pulmonary hypertension. 2010 , 27, 317-23	22
1769	Portopulmonary hypertension: short review. 2010 , 22, 385-90	23
1768	Inflammation and pulmonary hypertension. 2010 , 18, 67-72	22
1767	The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options. 2010 , 6, 343-55	44
1766	Les cellules endothéliales circulantes et les précurseurs endothéliaux: produits de thérapie cellulaire ou biomarqueurs des pathologies vasculaires?. 2010 , 22, 289-300	
1765	Inhalational therapy for pulmonary arterial hypertension: current status and future prospects. 2010 , 27, 313-70	22
1764	Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation. 2011 , 1, 123-39	3
1763	Optical coherence tomography as a novel diagnostic tool for distal type chronic thromboembolic pulmonary hypertension. 2010 , 74, 1742-4	47
1762	Identification of new prognostic factors of pulmonary hypertension. 2010 , 74, 1965-71	37
1761	[Scleroderma]. 2010 , 51, 30-8	5

1760	[Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax]. 2010 , 51 Suppl 1, 255-63	4
1759	CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. 2010 , 188, 191-7	21
1758	Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. 2010 , 188, 365-73	81
1757	Diagnostik der pulmonalen Hypertonie. 2010 , 7, 174-186	
1756	Pulmonale Hypertonie bei Lungenerkrankungen. 2010 , 7, 187-191	
1755	Diagnosis and management of pulmonary hypertension in systemic sclerosis. 2010 , 12, 8-18	21
1754	A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. 2010 , 26, 509-18	50
1753	Medical therapy for pediatric pulmonary arterial hypertension. 2010 , 157, 528-32	32
1752	Management of pulmonary arterial hypertension in children. 2010 , 11, 240-5	7
1751	[Pulmonary hypertension: the contribution of MDCT to the diagnosis of its different types]. 2010 , 52, 500-12	7
1750	Endothelial progenitor cells in pulmonary arterial hypertension. 2010 , 20, 22-9	32
1749	Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension. 2010 , 105, 1186-91	57
1748	Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. 2010 , 106, 117-24	107
1747	Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation?. 2010 , 106, 1657-62	16
1746	A 13-Year-Old With Fatigue, Chest Pain, and Dyspnea. 2010 , 11, 143-149	
1745	Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. 2010 , 76, 865-73	52
1744	Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. 2010 , 62, 3093-100	41
1743	Computed tomography and magnetic resonance imaging of pulmonary hypertension: Pulmonary vessels and right ventricle. 2010 , 32, 1313-24	22

1742	Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis. 2010 , 8, 25	15
1741	[Therapy according to current guidelines. Practical management of pulmonary arterial hypertension.]. 2010 , 39, 448-52	
1740	Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. 2010 , 117, 565-74	109
1739	Schistosomiasis associated pulmonary hypertension. 2010 , 64, 25-8	25
1738	Pulmonary arterial hypertension in adults with congenital heart disease. 2010 , 64, 13-24	8
1737	Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man. 2010 , 64, 5-13	20
1736	Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. 2010 , 64, 15-22	8
1735	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. 2010 , 15, 1226-32	29
1734	Pulmonary hypertension is not a diagnosis. 2010 , 65, 575-9	1
1733	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. 2010 , 6, 273-80	21
1732	Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. 2010 , 6, 359-66	15
1731	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. 2010 , 2, 151-61	18
1730	Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. 2010 , 17, 301-34	47
1729	Inhaled treprostinil and pulmonary arterial hypertension. 2010 , 6, 1115-24	6
1728	Recent Updates in Both the Diagnosis and Treatment Options that Impact the Clinical Treatment of Pulmonary Arterial Hypertension. 2010 , 2, CMT.S4192	
1727	Diagnosis and treatment of pulmonary hypertension: an update. 2010 , 36, 795-811	18
1726	Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. 2010 , 121, 2045-66	367
1725	PPARGgamma as a potential therapeutic target in pulmonary hypertension. 2010 , 4, 143-60	35

1724	Management of dyspnea in interstitial lung disease. 2010 , 4, 69-75	13
1723	Management of dyspnea in advanced pulmonary arterial hypertension. 2010 , 4, 76-84	11
1722	Three-dimensional structure of pulmonary capillary vessels in patients with pulmonary hypertension. 2010 , 121, 2151-3	17
1721	Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. 2010 , 182, 661-8	91
1720	ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). 2010 , 31, 2915-57	1708
1719	Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. 2010 , 49, 2147-53	11
1718	Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. 2010 , 56, 696-708	79
1717	Elevated pulmonary artery systolic pressure in patients with coronary artery disease and left ventricular dyssynchrony. 2010 , 12, 1067-75	5
1716	Ischaemia-modified albumin in pulmonary hypertension. 2010 , 15, 238-42	4
1715	Idiopathic pulmonary arterial hypertension. 2010 , 3, 268-73	52
1714	New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. 2010 , 19, 469-88	24
1713	Clinical use of sildenafil in pulmonary artery hypertension. 2010 , 4, 13-9	11
1712	Severe α -thalassemia intermedia in a compound heterozygous patient for the -30 (T>A) α (+)-thalassemia mutation and the α (0) α (+)-Senegalese deletion. 2010 , 34, 505-8	1
1711	Optimising the management of pulmonary arterial hypertension patients: emergency treatments. 2010 , 19, 204-11	43
1710	Severe pulmonary hypertension in a young patient with end-stage renal disease on chronic hemodialysis. 2010 , 3, 184-6	5
1709	[Pulmonary hypertension caused by left heart disease]. 2010 , 10 Suppl 2, 42-6	1
1708	Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. 2010 , 35, 6-8	19
1707	Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. 2010 , 36, 986-90	24

1706	[Atrial septostomy in pulmonary hypertension]. 2010 , 10 Suppl 2, 27-30	2
1705	Pulmonary hypertension in women. 2010 , 8, 1549-58	31
1704	Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. 2010 , 137, 85S-94S	19
1703	Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. 2010 , 137, 52S-61S	71
1702	New echocardiographic prognostic factors for mortality in pulmonary arterial hypertension. 2010 , 11, 516-22	62
1701	[Pulmonary hypertension - historical development, current therapy and perspectives]. 2010 , 64, 577-82	3
1700	Pulmonary arterial hypertension and lung transplantation. 2010 , 31, 147-60	12
1699	Clinical year in review I: interstitial lung disease, pulmonary vascular disease and venous thromboembolism, diagnostic imaging, and lung cancer. 2010 , 7, 297-304	
1698	Sarcoidosis-associated pulmonary hypertension: assessment and management. 2010 , 31, 494-500	16
1697	Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time!. 2010 , 181, 202-3	10
1696	Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. 2010 , 182, 1153-60	117
1695	[Pulmonary hypertension due to left heart disease: recommendations of the Cologne Consensus Conference 2010]. 2010 , 135 Suppl 3, S102-14	1
1694	Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. 2010 , 6, 285-96	33
1693	Systemic sclerosis-associated pulmonary arterial hypertension. 2010 , 181, 1285-93	74
1692	Th2 inflammation, hypoxia-induced mitogenic factor/FIZZ1, and pulmonary hypertension and vascular remodeling in schistosomiasis. 2010 , 181, 203-5	12
1691	Update on pulmonary hypertension 2009. 2010 , 181, 1020-6	12
1690	Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. 2010 , 13, 393-402	35
1689	Bosentan. 2010 , 11, 1023-34	6

1688	Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics. 2010 , 23, 225-39; quiz 332-4		114
1687	[Guidelines for the diagnosis and treatment of pulmonary hypertension]. 2010 , 27, 141-50		5
1686	[New international guidelines on pulmonary hypertension]. 2010 , 27, 110-1		1
1685	Emerging and established parasitic lung infestations. 2010 , 24, 579-602		14
1684	Diagnosis: imaging techniques. 2010 , 31, 641-57		10
1683	[Pulmonary hypertension of the elderly: not so infrequent]. 2010 , 27, 8-9		
1682	[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension]. 2010 , 27, 103-5		
1681	Accuracy of Doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. 2010 , 5, e15670		16
1680	Pulmonary manifestations of the antiphospholipid antibody syndrome. 2010 , 31, 537-45		27
1679	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 267; author reply 267	15.1	4
1678	Reply. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 267	15.1	
1677	Survival in schistosomiasis-associated pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 715-20	15.1	51
1676	Imaging in pulmonary hypertension. 2010 , 3, 1287-95		56
1675	Classification de l'hypertension pulmonaire. 2010 , 2, 132-136		
1674	The right heart and pulmonary circulation (III). The pulmonary circulation in heart failure. 2010 , 63, 334-45		8
1673	Evidence-Based Management of Right Heart Failure: a Systematic Review of an Empiric Field. 2010 , 63, 451-471		2
1672	Current diagnostic and prognostic assessment of pulmonary Hypertension. 2010 , 63, 583-96		3
1671	Current therapeutic approaches to pulmonary arterial hypertension. 2010 , 63, 708-24		2

1670	Pulmonary hypertension in congenital shunts. 2010 , 63, 1179-93	5
1669	Pulmonary hypertension: The contribution of MDCT to the diagnosis of its different types. 2010 , 52, 500-512	6
1668	Chronic thromboembolic pulmonary hypertension. 2010 , 31, 741-58	29
1667	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. 2010 , 181, 851-61	209
1666	Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial hypertension. 2010 , 29, 174-80	16
1665	Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. 2010 , 29, 865-72	39
1664	Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. 2010 , 29, 1150-8	6
1663	The relationship between pulmonary artery and pulmonary capillary wedge pressure for the diagnosis of pulmonary vascular disease. 2010 , 19, 38-42	4
1662	[Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. 2010 , 39, 134-43	8
1661	Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. 2010 , 126, e418-22	33
1660	[Pulmonary arterial hypertension and malignant hematologic disorders]. 2010 , 31, 621-5	3
1659	Pulmonary veno-occlusive disease: recent progress and current challenges. 2010 , 104 Suppl 1, S23-32	78
1658	Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. 2010 , 104, 1588-607	70
1657	Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. 2010 , 104, 481-96	74
1656	Pulmonary hypertension associated with bone marrow transplantation. 2010 , 2, e23-e27	4
1655	Tratamiento basado en la evidencia de la insuficiencia cardiaca derecha: una revisi3n sistem3tica de un campo emp3rico. 2010 , 63, 451-471	25
1654	La circulaci3n pulmonar en la insuficiencia cardiaca. 2010 , 63, 334-345	20
1653	Evaluaci3n diagn3stica y pron3stica actual de la hipertensi3n pulmonar. 2010 , 63, 583-596	13

1652	Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. 2010 , 63, 708-724	15
1651	Hipertensión pulmonar en los cortocircuitos congénitos. 2010 , 63, 1179-1193	20
1650	Hipertensión pulmonar. 2010 , 10, 4505-4512	
1649	Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. 2010 , 176, 1130-8	183
1648	[Diagnosis and classification of pulmonary hypertension]. 2010 , 39 Suppl 1, 1S3-15	1
1647	[A critical analysis of survival in idiopathic pulmonary arterial hypertension]. 2010 , 39 Suppl 1, 1S41-5	3
1646	The Ottawa Pulmonary Hypertension Symposium. 2010 , 26, 3B-4B	
1645	Pulmonary hypertension: Classification and treatment. 2010 , 26, 5B-11B	1
1644	Hypertension artérielle pulmonaire. 2010 , 2, 27-37	
1643	Riociguat for pulmonary hypertension. 2010 , 6, 155-66	24
1642	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. 2010 , 122, 156-63	1035
1641	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. 2010 , 6, 19-35	17
1640	Role of somatic mutations in vascular disease formation. 2010 , 10, 173-85	27
1639	Emerging drugs for pulmonary hypertension. 2010 , 15, 71-85	11
1638	Comprehensive MDCT evaluation of patients with pulmonary hypertension: diagnosing underlying causes with the updated Dana Point 2008 classification. 2011 , 197, W471-81	13
1637	Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. 2011 , 40, 127-32	42
1636	Pulmonary veno-occlusive disease: advances in clinical management and treatments. 2011 , 5, 217-29; quiz 230-1	33
1635	Management of acquired cardiac disease in the obstetric patient. 2011 , 15, 85-97	2

1634	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. 2011 , 13, 114	6
1633	Ambrisentan. 2011 , 11, 215-26	33
1632	Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. 2011 , 9, 377-87	24
1631	Pulmonary hypertension in children with sickle cell disease. 2011 , 5, 233-43	11
1630	Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. 2011 , 141, 1673-9	60
1629	[Diagnostic and prognostic evaluation in patients with pulmonary hypertension]. 2011 , 47 Suppl 7, 2-6	
1628	Facteurs pronostiques dans l'HTAP idiopathique. 2011 , 3, S42-S48	1
1627	Mechanisms of disease: pulmonary arterial hypertension. 2011 , 8, 443-55	472
1626	Transplantation pulmonaire. 2011 , 3, 166-172	
1625	Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. 2011 , 86, 105-12	46
1624	Assessment of pulmonary hypertension what CT and MRI can provide. 2011 , 18, 437-53	19
1623	Pulmonary arterial hypertension: a comparison between children and adults. 2011 , 37, 665-77	140
1622	The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. 2011 , 63, 504-11	117
1621	Chronic thromboembolic pulmonary hypertension. 2011 , 364, 351-60	241
1620	Pregnancy and pulmonary hypertension. 2011 , 32, 165-174	14
1619	Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. 2011 , 9, 293-303	35
1618	Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. 2011 , 32, 3137-46	74
1617	Pulmonary arterial hypertension. 2011 , 23, 645-59	1

1616 Molecular Basis of Pulmonary Hypertension in Left Heart Failure. **2011**, 259-271

1615 Riociguat for the treatment of pulmonary hypertension. **2011**, 20, 567-76

69

1614 [Pulmonary arterial hypertension related to HIV: is inflammation related to IL-6 the cornerstone?]. **2011**, 67, 250-7

6

1613 Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension. **2011**, 17, 265-71

14

1612 Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients. **2011**, 17, 1012-7

32

1611 Portopulmonary hypertension: from diagnosis to treatment. **2011**, 22, 441-7

13

1610 Association of anemia and long-term survival in patients with pulmonary hypertension. **2011**, 150, 291-5

30

1609 Lung involvement in systemic sclerosis. **2011**, 40, e3-e17

21

1608 Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. **2011**, 40, e65-78

21

1607 Pulmonary manifestations of Sjögren's syndrome. **2011**, 40, e49-64

44

1606 [Combination of pulmonary fibrosis and emphysema: Is tobacco once again the protagonist?]. **2011**, 136, 18-20

1

1605 Key role of the RhoA/Rho kinase system in pulmonary hypertension. **2011**, 24, 1-14

50

1604 Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension. **2011**, 64, 667-73

12

1603 Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. **2011**, 105, 818-27

44

1602 Conditions associated with severe carbon monoxide diffusion coefficient reduction. **2011**, 105, 1248-56

22

1601 [Innovation for the cure of pulmonary arterial hypertension]. **2011**, 40 Suppl 1, 1S1-2

1600 [Novel immunopathological approaches to pulmonary arterial hypertension]. **2011**, 40 Suppl 1, 1S3-13

1

1599 [Resting and exercise hemodynamics in pulmonary arterial hypertension]. **2011**, 40 Suppl 1, 1S28-38

0

1598	[Pulmonary hypertension in interstitial lung diseases: diagnostic and therapeutic approach in 2011?]. 2011 , 40 Suppl 1, 1S39-45		0
1597	[Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls]. 2011 , 40 Suppl 1, 1S46-53		0
1596	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. 2011 , 279-305		6
1595	Inhaled iloprost for therapy in pulmonary arterial hypertension. 2011 , 5, 145-52		8
1594	Tadalafil for the treatment of pulmonary arterial hypertension. 2011 , 5, 315-28		7
1593	Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1053-61	15.1	48
1592	Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. 2011 , 27, 1763-8		46
1591	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. 2011 , 12, 1585-96		19
1590	Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. 2011 , 4, 197-205		3
1589	Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. 2011 , 25, 687-704		49
1588	Long-Term (5 Years) Effects of Bosentan in Patients With Pulmonary Arterial Hypertension. 2011 , 64, 667-673		
1587	Cologne Consensus Conference on pulmonary hypertension. 2011 , 154 Suppl 1, S1-2		4
1586	Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. 2011 , 154 Suppl 1, S34-44		21
1585	[Update on pediatric cardiology and congenital heart disease: imaging techniques, pulmonary arterial hypertension, hybrid treatment, and surgical treatment]. 2011 , 64 Suppl 1, 59-65		7
1584	Treatment of schistosomiasis-associated pulmonary hypertension. 2011 , 37, 272-6		14
1583	A 7-year-old with pulmonary hypertension. 2011 , 2011, bcr0220113843		2
1582	Echocardiography in Pulmonary Hypertension. 2011 ,		
1581	Dyspnea in Pulmonary Arterial Hypertension. 2011 ,		

1580	Eisenmenger Syndrome. 2011 , 358-370	1
1579	Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review. 2011 , 18, 157-62	5
1578	Long-term survival in idiopathic pulmonary arterial hypertension associated with massive pulmonary artery dilation. 2011 , 18, e50-1	2
1577	Familial pulmonary capillary hemangiomatosis early in life. 2011 , 2011, 827591	7
1576	Diagnosis and management of pulmonary arterial hypertension. 2011 , 2011, 845864	23
1575	Cell-specific dual role of caveolin-1 in pulmonary hypertension. 2011 , 2011, 573432	32
1574	Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of Canadian pulmonary hypertension physicians. 2011 , 18, 230-4	6
1573	Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements. 2011 , 18, e70-2	5
1572	Therapeutic strategies in pulmonary hypertension. 2011 , 2, 21	10
1571	Prostacyclin: an inflammatory paradox. 2011 , 2, 24	69
1570	ACE2 improves right ventricular function in a pressure overload model. 2011 , 6, e20828	51
1569	A histopathological study of pulmonary hypertension in connective tissue disease. 2011 , 60, 411-7	19
1568	Recent progress in understanding pediatric pulmonary hypertension. 2011 , 23, 298-304	41
1567	Pulmonary hypertension in critical care. 2011 , 17, 439-48	20
1566	Portopulmonary hypertension. 2011 , 45, 703-10	10
1565	Mesenchymal stem cells restore lung function by recruiting resident and nonresident proteins. 2011 , 20, 1561-74	28
1564	Pulmonary Hypertension in Interstitial Lung Disease. 2011 , 18, 222-229	
1563	Increased right ventricular Septomarginal trabeculation mass is a novel marker for pulmonary hypertension: comparison with ventricular mass index and right ventricular mass. 2011 , 46, 567-75	25

1562	Complication vasculaire pulmonaire des cardiopathies congénitales. 2011 , 8, 1-13	
1561	Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. 2011 , 139, 109-14	107
1560	Human Herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. 2011 , 139, 1310-1316	24
1559	Naming and understanding rare diseases: International Classification of Diseases coding and the epidemiologic designations of idiopathic pulmonary arterial hypertension. 2011 , 139, 482-483	3
1558	The impact of combined pulmonary fibrosis and emphysema on mortality. 2011 , 15, 1111-6	30
1557	The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. 2011 , 139, 128-37	231
1556	International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies. 2011 , 139, 497-504	53
1555	Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. 2011 , 140, 42-47	32
1554	Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. 2011 , 140, 19-26	167
1553	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. 2011 , 118, 855-64	179
1552	Bad blood, bad endothelium: ill fate?. 2011 , 117, 3479-80	6
1551	Recent progress in the management of pulmonary hypertension. 2011 , 75, 1801-10	65
1550	Pulmonary artery distensibility index is a non-invasive useful marker of pulmonary arterial hypertension progression. 2011 , 75, 2058-9	2
1549	Recent advances in adult congenital heart disease. 2011 , 75, 2287-95	20
1548	Pulmonary arterial hypertension: An overview. 2011 , 6, 268-277	1
1547	A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. 2011 , 75, 677-82	17
1546	2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. 2011 , 60, 419-24	17
1545	Pulmonary hypertension in sarcoidosis: a review. 2011 , 16, 69-77	55

1544	The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia. 2011 , 19, 89-94	3
1543	New perspectives for the treatment of pulmonary hypertension. 2011 , 163, 125-40	47
1542	Inflammation, immunological reaction and role of infection in pulmonary hypertension. 2011 , 17, 7-14	60
1541	Current management approaches to portopulmonary hypertension. 2011 , 65, 11-8	14
1540	Microarray studies in pulmonary arterial hypertension. 2011 , 65, 19-28	16
1539	Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. 2011 , 65, 15-34	63
1538	Transforming growth factor signalling: a common pathway in pulmonary arterial hypertension and systemic sclerosis. 2011 , 65, 35-43	8
1537	Pulmonary hypertension and right ventricular function in advanced heart failure. 2011 , 17, 189-98	24
1536	Evaluation and Management of the Adult Patient With Pulmonary Hypertension. 2011 , 7, 409-416	2
1535	Reversible severe pulmonary hypertension in obesity hypoventilation and Mohr syndrome. 2011 , 4, 30-32	
1534	Two cases of stem cell therapy for pulmonary hypertension: A clinical report. 2011 , 4, 70-74	1
1533	Pulmonary hypertension in systemic sclerosis. 2011 , 41, 19-37	31
1532	Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. 2011 , 54, 154-67	59
1531	A case of pulmonary capillary hemangiomatosis with pulmonary fibrosis associated with MMP-9 related pulmonary remodeling. 2011 , 61, 306-12	9
1530	Sarcoidosis with pulmonary hypertension exacerbated by Takayasu-like large vessel vasculitis. 2011 , 61, 546-50	11
1529	Pulmonary arterial hypertension. 2011 , 36, 461-517	40
1528	Identifying high risk in adults with congenital heart disease and atrial arrhythmias. 2011 , 108, 723-8	50
1527	The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. 2011 , 5, 195-206	15

1526	Genetic counselling for pulmonary arterial hypertension: a matter of variable variability. 2011 , 19, 89-92	7
1525	Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. 2011 , 19, 509-13	9
1524	Pulmonary hypertension, how to diagnose and who to treat?. 2011 , 19, 493-4	2
1523	Pulmonary arterial hypertension and lung transplantation. 2011 , 5, 441-54	22
1522	Complicated Pregnancies in Patients with Autoimmune Systemic Diseases. 2011 , 331-344	
1521	Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. 2011 , 100, 879-85	21
1520	Sleep quality, depression, and quality of life in patients with pulmonary hypertension. 2011 , 189, 141-9	45
1519	Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. 2011 , 14, 17-27	46
1518	Pro-angiogenic hematopoietic progenitor cells and endothelial colony-forming cells in pathological angiogenesis of bronchial and pulmonary circulation. 2011 , 14, 411-22	39
1517	Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. 2011 , 89, 971-83	36
1516	A case of non-cardiogenic acute pulmonary edema in a patient with POEMS syndrome-associated pulmonary arterial hypertension. 2011 , 90, 489-90	4
1515	Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children. 2011 , 32, 828-33	4
1514	Pulmonary arterial hypertension: what the large pulmonary arteries tell us. 2011 , 32, 759-65	3
1513	Anorexigènes et maladies cardiovasculaires : les liaisons dangereuses. 2011 , 20, 424-435	2
1512	Evaluation of pulmonary hypertension in a child: role of computed tomography. 2011 , 78, 1417-9	3
1511	Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. 2011 , 28, 251-69	30
1510	Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. 2011 , 2, 29-33	6
1509	Treatment for pulmonary hypertension including lung transplantation. 2011 , 59, 538-46	2

1508	Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?. 2011 , 11, 30	43
1507	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. 2011 , 12, 119	64
1506	Role of the gap junctions in the contractile response to agonists in pulmonary artery from two rat models of pulmonary hypertension. 2011 , 12, 30	30
1505	GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. 2011 , 12, 62	66
1504	Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. 2011 , 46, 45-59	13
1503	Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension. 2011 , 33, 225-31	25
1502	Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. 2011 , 86, 123-54	113
1501	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. 2011 , 63, 2456-64	87
1500	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. 2011 , 63, 2790-6	40
1499	Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. 2011 , 63, 3531-9	23
1498	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. 2011 , 63, 3522-30	199
1497	Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. 2011 , 12, 1845-64	3
1496	Schistosomiasis and pulmonary hypertension. 2011 , 5, 675-81	22
1495	Gene therapy for pulmonary hypertension: prospects and challenges. 2011 , 11, 133-43	17
1494	Advances in the management of pediatric pulmonary hypertension. 2011 , 56, 1314-39; discussion 1339-40	32
1493	Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment, and Dana Point World Symposium Highlights. 2011 , 7, 279-288	1
1492	Right heart on multidetector CT. 2011 , 84 Spec No 3, S306-23	32
1491	Treatment of pulmonary arterial hypertension: great expectations!. 2011 , 38, 403-5	1

1490	Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. 2011 , 183, 268-76	157
1489	VEGF receptor inhibition as a model of pulmonary hypertension in mice. 2011 , 184, 1103-5	5
1488	Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience. 2011 , 123, 32-45	2
1487	An uncommon cause of pulmonary hypertension. 2011 , 183, 1112	1
1486	Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. 2011 , 45, 1-15	153
1485	Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. 2011 , 89, 542-52	73
1484	Pulmonary arterial hypertension in connective tissue diseases. 2011 , 60, 405-9	7
1483	Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. 2011 , 45, 311-22	98
1482	Combination therapy in pulmonary arterial hypertension: a meta-analysis. 2011 , 120, 157-65	51
1481	Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. 2011 , 183, 649-58	159
1480	Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. 2011 , 184, 1400-8	90
1479	[Right heart catheterization in pulmonary hypertension]. 2011 , 136, 2601-16; quiz 2617-20	15
1478	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. 2011 , 12, 2583-93	7
1477	Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension. 2011 , 1, 1929-41	9
1476	Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. 2011 , 5, 163-71	15
1475	Perioperative Management of Patients With Pulmonary Hypertension. 2011 , 39, 126-133	
1474	Defining the phenotypes for pulmonary hypertension associated with diastolic heart failure. 2011 , 4, 238-40	7
1473	The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review. 2011 , 20, 1047-56	27

1472	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. 2011 , 124, 1973-81	630
1471	Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. 2011 , 1, 389-98	24
1470	Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. 2011 , 4, 692-9	86
1469	Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. 2011 , 4, 257-65	212
1468	Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. 2011 , 123, 1227-32	71
1467	A hemodynamic study of pulmonary hypertension in sickle cell disease. 2011 , 365, 44-53	354
1466	Bosentan for the treatment of adult pulmonary hypertension. 2011 , 7, 19-37	9
1465	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. 2011 , 31, e1-10	6
1464	Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension. 2011 , 139, 115-21	26
1463	Pulmonary arterial hypertension in china: promising news and some surprises. 2011 , 140, 276-278	
1462	Can pulmonary arterial hypertension be diagnosed by an elevated pulmonary capillary wedge pressure outside of the guideline criteria?. 2011 , 140, 828-829	
1461	Cardiovascular disorders associated with obstructive sleep apnea. 2011 , 46, 197-266	38
1460	Paracrine proliferative signaling by senescent cells in world health organization group 3 pulmonary hypertension: age corrupting youth?. 2011 , 109, 476-9	4
1459	Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. 2011 , 92, 375-84	62
1458	Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. 2011 , 32, 2438-45	65
1457	Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. 2011 , 140, 1016-1024	73
1456	Discerning pulmonary venous from pulmonary arterial hypertension without the help of a catheter. 2011 , 4, 235-7	14
1455	Pharmacokinetic evaluation of ambrisentan. 2011 , 7, 371-80	14

1454	Genomics and proteomics of pulmonary vascular disease. 2011 , 1, 467-83	5
1453	Vascular abnormalities in human newborns with pulmonary hypertension. 2011 , 5, 245-56	21
1452	The value of tools to assess pulmonary arterial hypertension. 2011 , 20, 222-35	23
1451	Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. 2011 , 124, 1755-64	196
1450	Is peroxisome proliferator-activated receptor gamma (PPAR γ) a therapeutic target for the treatment of pulmonary hypertension?. 2011 , 1, 33-47	31
1449	Cell-based therapies in pulmonary hypertension: who, what, and when?. 2011 , 301, L9-L11	6
1448	Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. 2011 , 184, 1114-24	199
1447	The genetics of pulmonary arterial hypertension in the post-BMPR2 era. 2011 , 1, 305-19	44
1446	Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome. 2011 , 2011, 351672	5
1445	Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. 2011 , 1, 250-258	38
1444	A critical role for the protein apoptosis repressor with caspase recruitment domain in hypoxia-induced pulmonary hypertension. 2011 , 124, 2533-42	30
1443	Overview of current therapeutic approaches for pulmonary hypertension. 2011 , 1, 138-59	34
1442	Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. 2011 , 32, 2489-98	106
1441	Viral infection and pulmonary hypertension: is there an association?. 2011 , 5, 207-16	32
1440	Lung transplantation for pulmonary hypertension. 2011 , 1, 182-91	31
1439	What is the prognostic significance of pulmonary hypertension in heart failure?. 2011 , 4, 541-5	25
1438	Combination therapy for the treatment of pulmonary arterial hypertension. 2011 , 5, 419-30	18
1437	Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension. 2011 , 301, L315-26	28

1436	Pulmonary hypertension secondary to interstitial lung disease. 2011 , 5, 179-89	16
1435	Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphism. 2011 , 1, 377-82	9
1434	Pulmonary hypertension: a fatal complication of neurofibromatosis type 1. 2011 , 56, 1844-8	10
1433	Programmatic change: lung disease research in the era of induced pluripotency. 2011 , 301, L830-5	6
1432	Classification of pediatric pulmonary hypertensive vascular disease: Does it need to be different from the adult classification?. 2011 , 1, 134-7	5
1431	A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. 2011 , 1, 286-298	171
1430	Surgical treatment of pulmonary hypertension: Lung transplantation. 2011 , 1, 327-33	22
1429	mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. 2011 , 25, 1922-33	88
1428	Imaging in pulmonary hypertension, part 1: clinical perspectives, classification, imaging techniques and imaging algorithm. 2012 , 88, 271-9	23
1427	Targeted approaches to the treatment of pulmonary hypertension. 2012 , 6, 147-59	11
1426	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. 2012 , 40, 630-40	58
1425	Pulmonary artery and right ventricle assessment in pulmonary hypertension: correlation between functional parameters of ECG-gated CT and right-side heart catheterization. 2012 , 53, 720-7	20
1424	Pulmonary arterial hypertension: an imaging review comparing MR pulmonary angiography and perfusion with multidetector CT angiography. 2012 , 85, 1446-56	15
1423	Three-dimensional analysis of right ventricular shape and function in pulmonary hypertension. 2012 , 2, 34-40	34
1422	Pulmonary hypertension in pregnancy: critical care management. 2012 , 2012, 709407	23
1421	Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. 2012 , 39, 1265-74	58
1420	Enhanced store-operated Ca^{2+} entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats. 2012 , 302, C77-87	57
1419	Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. 2012 , 125, 2353-62	47

1418	In vivo and in vitro measurements of pulmonary arterial stiffness: A brief review. 2012 , 2, 505-17	28
1417	Severe pulmonary hypertension: The role of metabolic and endocrine disorders. 2012 , 2, 148-54	23
1416	The WHO classification of pulmonary hypertension: A case-based imaging compendium. 2012 , 2, 107-21	34
1415	Leptin levels predict survival in pulmonary arterial hypertension. 2012 , 2, 214-9	16
1414	Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. 2012 , 11, 51-61	41
1413	A process-based review of mouse models of pulmonary hypertension. 2012 , 2, 415-33	19
1412	Pulmonary arterial hypertension: advances in pathophysiology and management. 2012 , 44, 4-11	11
1411	Peroxisome proliferator-activated receptor gamma (PPAR γ) regulates thrombospondin-1 and Nox4 expression in hypoxia-induced human pulmonary artery smooth muscle cell proliferation. 2012 , 2, 483-91	28
1410	Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. 2012 , 5, 336-43	268
1409	Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. 2012 , 19, 300-14	8
1408	Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. 2012 , 27, 262-72	13
1407	Advances in pediatric pulmonary arterial hypertension. 2012 , 27, 70-81	25
1406	Type 1 neurofibromatosis and pulmonary hypertension: a report of two cases and a review. 2012 , 4, 27-30	4
1405	Development and characterization of an animal model of severe pulmonary arterial hypertension. 2012 , 49, 33-42	28
1404	A new approach to kinematic feature extraction from the human right ventricle for classification of hypertension: a feasibility study. 2012 , 57, 7905-22	13
1403	The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study. 2012 , 2, e000806	29
1402	Experiences with treprostinil in the treatment of pulmonary arterial hypertension. 2012 , 6, 269-76	6
1401	Current role of imaging in the diagnosis and management of pulmonary hypertension. 2012 , 198, 1320-31	20

1400	Pulmonary arterial hypertension in systemic sclerosis is associated with profound impairment of microvascular endothelium-dependent vasodilatation. 2012 , 39, 100-5	14
1399	Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination. 2012 , 97, 2217-22	12
1398	Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. 2012 , 39, 276-85	57
1397	Lung morphology assessment with balanced steady-state free precession MR imaging compared with CT. 2012 , 263, 569-77	40
1396	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. 2012 , 6, 255-65	7
1395	The implications of stem cell applications for diseases of the respiratory system. 2013 , 130, 39-54	
1394	Chronic thromboembolic pulmonary hypertension: an underdiagnosed entity?. 2012 , 40, 71-9	9
1393	Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension. 2012 , 186, 291-2	10
1392	Progress in pulmonary arterial hypertension pathology: relighting a torch inside the tunnel. 2012 , 186, 210-2	21
1391	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. 2012 , 14, 946-53	22
1390	Pathophysiology of pulmonary hypertension in acute lung injury. 2012 , 302, L803-15	78
1389	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. 2012 , 52, 1784-805	54
1388	New mechanisms of pulmonary arterial hypertension: role of Ca ²⁺ signaling. 2012 , 302, H1546-62	132
1387	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. 2012 , 11, 1003-11	16
1386	Pulmonary hypertension associated with congenital heart disease: a practical review for the pediatric cardiologist. 2012 , 7, 575-83	9
1385	Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. 2012 , 59, 1170-8	99
1384	A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. 2012 , 302, L977-91	129
1383	Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. 2012 , 125, 113-22	237

1382	Right ventricular hypertrophy with heart failure in Holstein heifers at elevation of 1,600 meters. 2012 , 24, 867-77	23
1381	National Heart, Lung, and Blood Institute Workshop: improving outcomes for pulmonary vascular disease. 2012 , 125, 2165-70	17
1380	Pulmonary hypertension associated with Ehrlichia canis infection in a dog. 2012 , 170, 676	3
1379	The monocrotaline model of pulmonary hypertension in perspective. 2012 , 302, L363-9	264
1378	Imaging in pulmonary hypertension, part 2: Large vessel diseases. 2012 , 88, 317-25	14
1377	The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension. 2012 , 2012, 106576	11
1376	Persistent pulmonary hypertension of non cardiac cause in a neonatal intensive care unit. 2012 , 2012, 818971	14
1375	Pathogenic role of store-operated and receptor-operated Ca^{2+} channels in pulmonary arterial hypertension. 2012 , 2012, 951497	15
1374	Characterization of pulmonary venous hypertension patients with reactive pulmonary hypertension as compared to proportional pulmonary hypertension. 2012 , 83, 494-8	8
1373	Protective effects of methylsulfonylmethane on hemodynamics and oxidative stress in monocrotaline-induced pulmonary hypertensive rats. 2012 , 2012, 507278	19
1372	Comparison of ^{18}F -FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. 2012 , 2, 365-72	50
1371	Pulmonary Hypertension Secondary to COPD. 2012 , 2012, 203952	27
1370	Reversible pulmonary hypertension in a kidney transplant with patent A-V fistula. 2012 , 5, 347-9	3
1369	Combined pulmonary fibrosis and emphysema syndrome: a review. 2012 , 141, 222-231	216
1368	Improving outcomes for pulmonary vascular disease. 2012 , 185, 1015-20	18
1367	Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. 2012 , 40, 612-7	31
1366	Pulmonary hypertension in dialysis patients: a prevalent, risky but still uncharacterized disorder. 2012 , 27, 3674-7	2
1365	Pulmonary hypertension: a guide for GPs. 2012 , 62, e795-7	4

1364	Calcium channel blockers for pulmonary arterial hypertension. 2012,	0
1363	Drug- and Toxin-Induced Pulmonary Arterial Hypertension. 2012, 76-84	
1362	Portopulmonary hypertension: a report from the US-based REVEAL Registry. 2012, 141, 906-915	171
1361	Gh̃tique de l'hypertension artfielle pulmonaire : du fondamental au conseil gh̃tique. 2012, 9, 1-9	
1360	Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts. 2012, 8, 116-122	
1359	Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. 2012, 141, 651-660	51
1358	Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. 2012, 142, 869-876	40
1357	Multidetector computed tomography for detection and characterization of pulmonary hypertension in consideration of WHO classification. 2012, 36, 175-80	23
1356	Predictors of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Arterial Hypertension. 2012, 14, 283-292	11
1355	Pulmonary Veno-Occlusive Disease. 2012, 149-160	
1354	[The cutting-edge of medicine; progress in the diagnosis and treatment of mixed connective tissue disease]. 2012, 101, 1413-9	1
1353	Aortic valve disease. 193-199	
1352	Pulmonary vascular disease. 282-287	
1351	Inflammation in pulmonary arterial hypertension. 2012, 141, 210-221	279
1350	Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. 2012, 141, 363-373	118
1349	The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. 2012, 141, 923-928	38
1348	Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. 2012, 142, 1150-1157	79
1347	Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. 2012, 120, 1531-2	18

1346	Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials. 2012 , 2, 491-501	
1345	Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. 2012 , 76, 1501-8	69
1344	Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. 2012 , 76, 1235-44	37
1343	Mutations in bone morphogenetic protein receptor genes in pulmonary arterial hypertension patients. Possible involvement of BMPR1B. 2012 , 76, 1329-30	4
1342	Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. 2012 , 76, 1729-36	34
1341	Significance of electrocardiographic right ventricular hypertrophy in patients with pulmonary hypertension with or without right ventricular systolic dysfunction. 2012 , 51, 2277-83	6
1340	Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. 2012 , 76, 1737-43	38
1339	Clinical features of paediatric pulmonary hypertension: a registry study. 2012 , 379, 537-46	346
1338	Pulmonary hypertension in early life. 2012 , 379, 500-1	2
1337	Computed tomography and cardiac magnetic resonance imaging in pulmonary hypertension. 2012 , 55, 161-71	18
1336	Anesthesia and pulmonary hypertension. 2012 , 55, 199-217	44
1335	Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. 2012 , 126, 1087-98	105
1334	Imatinib mesylate for the treatment of pulmonary arterial hypertension. 2012 , 21, 119-34	50
1333	Administration of ketamine to children with pulmonary hypertension is safe: pro-con debate: Pro Argument. 2012 , 22, 1042-52	9
1332	Immune and inflammatory mechanisms in pulmonary arterial hypertension. 2012 , 55, 218-28	74
1331	Right Ventricular Anomalies. 2012 , 95-118	
1330	Pharmacotherapy for pulmonary hypertension. 2012 , 59, 1129-46	17
1329	Caveolin-1 expression during the progression of pulmonary hypertension. 2012 , 237, 956-65	25

1328	The pharmacological treatment of pulmonary arterial hypertension. 2012 , 64, 583-620	88
1327	Inhalation therapy to treat pulmonary arterial hypertension. 2012 , 1, 577-88	4
1326	Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. 2012 , 186, 897-908	219
1325	Tricuspid annular peak systolic velocity (S') in children and young adults with pulmonary artery hypertension secondary to congenital heart diseases, and in those with repaired tetralogy of Fallot: echocardiography and MRI data. 2012 , 25, 1041-9	47
1324	2-J�hriger mit pulmonaler Hypertonie und reduzierter k�rperlicher Belastbarkeit. 2012 , 160, 1190-1193	
1323	Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival. 2012 , 190, 645-9	18
1322	Pulmonary hypertension associated with veno-occlusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator. 2012 , 5, e44-e47	0
1321	Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary vasodilator therapy. 2012 , 5, e175-e178	
1320	Effect of vasodilators in patient with pulmonary hypertension associated with hemolytic anemia. 2012 , 6, e75-e77	1
1319	Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. 2012 , 160, 435-42	18
1318	Pulmonary hypertension-"state of the art" management in 2012. 2012 , 64, 60-73	2
1317	Genetics and pharmacogenomics in pulmonary arterial hypertension. 2012 , 8, 319-30	2
1316	Pulmonary hypertension in a child with mitochondrial A3243G point mutation. 2012 , 34, 866-8	19
1315	Congenital heart disease and pulmonary hypertension. 2012 , 8, 427-45	11
1314	Sleep-related breathing disorders in patients with schistosomal cor-pulmonale. 2012 , 61, 203-208	
1313	BDNF/TrkB signaling augments smooth muscle cell proliferation in pulmonary hypertension. 2012 , 181, 2018-29	35
1312	Pulmonary Hypertension. 2012 , 1, e172-e184	
1311	Imagerie des pathologies vasculaires du poumon. 2012 , 4, 80-86	

1310	Classification of pulmonary hypertension. 2012 , 8, 301-17	10
1309	Exercise-induced pulmonary hypertension. 2012 , 8, 485-95	28
1308	Syndrome h�pato-pulmonaire. 2012 , 4, 43-46	
1307	Right ventricular dysfunction in chronic lung disease. 2012 , 30, 243-56	33
1306	C�r pulmonaire chronique post embolique. 2012 , 4, 55-58	
1305	Late development of pulmonary arterial hypertension after arterial switch for transposition of the great arteries. 2012 , 65, 1064-5	6
1304	Recomenda��s da ESC para o tratamento da cardiopatia cong�nita no adulto (nova vers�o de 2010). 2012 , 31, 541.e1-541.e53	
1303	Late Development of Pulmonary Arterial Hypertension After Arterial Switch for Transposition of the Great Arteries. 2012 , 65, 1064-1065	1
1302	MicroRNAs as potential biomarkers of smoking-related diseases. 2012 , 6, 671-84	31
1301	Consenso sobre la clasificaci�n de la enfermedad vascular pulmonar hipertensiva en ni�os: Reporte del task force pedi�trico del Pulmonary Vascular Research Institute (PVRI) Panam�2011. 2012 , 19, 339-352	
1300	Hipertensi�n pulmonar a moderada altura en ni�os. 2012 , 19, 199-207	2
1299	Animal models of pulmonary hypertension: Rho kinase inhibition. 2012 , 109, 67-75	17
1298	Cardiac Diseases. 2012 , 28-74	1
1297	BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. 2012 , 5, 511-8	26
1296	17�Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. 2012 , 185, 965-80	119
1295	Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. 2012 , 185, 311-21	194
1294	Pulmonary Hypertension. 2012 , 710-721	1
1293	Hypoxic pulmonary vasoconstriction. 2012 , 92, 367-520	444

1292	Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/Rho kinase activation. 2012 , 180, 2268-75	27
1291	Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. 2012 , 110, 433-9	25
1290	Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension. 2012 , 110, 909-14	9
1289	Hemodynamics in pulmonary arterial hypertension: current and future perspectives. 2012 , 110, 9S-15S	33
1288	Pulmonary hypertension complicating sarcoidosis. 2012 , 41, e303-16	24
1287	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. 2012 , 31, 150-8	73
1286	Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. 2012 , 31, 467-77	34
1285	Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. 2012 , 31, 735-43	37
1284	Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review. 2012 , 31, 557-64	65
1283	New index improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices. 2012 , 161, 25-30	22
1282	Pulmonary hypertension in left heart disease: a review. 2012 , 156, 253-8	7
1281	Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. 2012 , 690, 176-82	9
1280	Evolving epidemiology of pulmonary arterial hypertension. 2012 , 186, 707-9	34
1279	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. 2012 , 64, 2995-3005	82
1278	Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. 2012 , 32, 838-55	11
1277	Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats. 2012 , 97, 676-86	23
1276	Gene expression analysis of a murine model with pulmonary vascular remodeling compared to end-stage IPAH lungs. 2012 , 13, 103	7
1275	Pulmonary hypertension in patients with Martorell hypertensive leg ulcer: a case control study. 2012 , 13, 45	

1274	Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. 2012 , 14, R213	66
1273	Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. 2012 , 74, 990-8	4
1272	Pulmonary arterial hypertension in connective tissue diseases. 2012 , 8, 413-25	47
1271	Imaging of congenital and acquired disorders of the pulmonary artery. 2012 , 41, 165-78	4
1270	Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. 2012 , 84, 477-84	30
1269	Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. 2012 , 66, 1117-24	
1268	Treatment of pulmonary arterial hypertension in connective tissue disease. 2012 , 72, 1039-56	2
1267	Approach to the Patient with Dyspnea. 2012 , 427-444	
1266	Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. 2012 , 123, 197-200	9
1265	The imaging of pulmonary hypertension. 2012 , 33, 535-51	24
1264	Actividad física y acelerómetros en el tratamiento de la HAP: una aproximación práctica a la vida real 2012 , 15, 1-3	
1263	RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness. 2012 , 5, 378-87	109
1262	Electrical and mechanical dyssynchrony in pediatric pulmonary hypertension. 2012 , 31, 825-30	11
1261	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. 2012 , 31, 913-33	165
1260	Arrhythmias in pulmonary arterial hypertension. 2012 , 55, 180-6	78
1259	Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery. 2012 , 55, 128-33	31
1258	World Health Organization Group III pulmonary hypertension. 2012 , 55, 119-27	21
1257	Why all pulmonary hypertensive patients need a heart catheter study?. 2012 , 34, 123-127	

1256	Reversible pulmonary hypertension associated with lungworm infection in a young cat. 2012 , 14, 465-74	31
1255	Beneficial effects of β -aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension. 2012 , 91, 693-8	13
1254	[Sporadic lymphangioleiomyomatosis and pulmonary hypertension. Clinical and pathologic study in patients undergoing lung transplantation]. 2012 , 138, 570-3	4
1253	Imaging of Pulmonary Hypertension. 2012 , 139-160	
1252	Pulmonary hypertension associated with left-sided heart disease. 2012 , 8, 447-59	24
1251	Pulmonary hypertension in parenchymal lung disease. 2012 , 8, 461-74	7
1250	Pulmonary Hypertension. 2012 , 589-600	
1249	The effect of endogenous estrogen on Doppler-estimated right ventricular systolic pressure during exercise. 2012 , 90, 1364-71	
1248	Tadalafil for the treatment of pulmonary arterial hypertension. 2012 , 13, 747-55	13
1247	Diagnostic dilemmas in pulmonary hypertension. 2012 , 8, 331-52	1
1246	Pediatric Pulmonary Hypertension. 2012 , 730-752	
1245	Smooth Muscle in the Normal and Diseased Pulmonary Circulation. 2012 , 1347-1358	0
1244	Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease. 2012 , 33, 1323-31	26
1243	Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension. 2012 , 33, 1332-42	6
1242	Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. 2012 , 12, 75	19
1241	Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. 2012 , 47, 679-87	63
1240	Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice. 2012 , 7, e32468	20
1239	Clinical impact of atrial fibrillation in patients with pulmonary hypertension. 2012 , 7, e33902	44

1238	Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. 2012 , 7, e35310	94
1237	Treatment of pulmonary hypertension. 2012 , 18, RA31-9	10
1236	Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. 2012 , 2012, 505274	71
1235	Perioperative anesthesiological management of patients with pulmonary hypertension. 2012 , 2012, 356982	30
1234	Atrial Septostomy. 2012 , 254-261	
1233	Pulmonary Hypertension. 2012 , 355-366	
1232	Molecular pathogenesis of pulmonary arterial hypertension. 2012 , 122, 4306-13	449
1231	Childhood Pulmonary Arterial Hypertension. 2012 , 1003-1018	
1230	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. 2012 , 59	
1229	A Pathophysiological Approach to Understanding Pulmonary Hypertension in Cardiac Surgery. 2012 , ,	
1228	Pulmonary hypertension: an emerging risk in hemoglobin disorders. 2012 , 1,	
1227	Superiority of desflurane over sevoflurane and isoflurane in the presence of pressure-overload right ventricle hypertrophy in rats. 2012 , 117, 1051-61	9
1226	Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. 2012 , 108, 1049-60	11
1225	Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders. 2012 , 94-104	
1224	Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. 2012 , 99, 876-85	6
1223	Hemodynamic profile of severity at pulmonary vasoreactivity test in schistosomiasis patients. 2012 , 99, 789-96	12
1222	Portopulmonary hypertension: an update. 2012 , 18, 881-91	73
1221	Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. 2012 , 69, 2805-31	15

1220	Cardiac sympathetic activation in patients with pulmonary arterial hypertension. 2012 , 302, R1153-7	39
1219	Pulmonary hypertension: how the radiologist can help. 2012 , 32, 9-32	90
1218	[Management of patients with pulmonary hypertension]. 2012 , 61, 574-77, 580-7	4
1217	Redefining the role of cardiovascular imaging in patients with pulmonary arterial hypertension. 2012 , 14, 366-73	7
1216	Pulmonary veno-occlusive disease: a misnomer?. 2012 , 42, 647-52; quiz 773-4	6
1215	Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving \geq years and those surviving \leq years after baseline right-sided cardiac catheterization. 2012 , 109, 1514-20	20
1214	Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. 2012 , 109, 1504-9	61
1213	[Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension]. 2012 , 61, 1-7	
1212	sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model. 2012 , 206, 178-94	13
1211	Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. 2012 , 18, 151-7	23
1210	Systolic right ventricular function in children and young adults with pulmonary artery hypertension secondary to congenital heart disease and tetralogy of Fallot: tricuspid annular plane systolic excursion (TAPSE) and magnetic resonance imaging data. 2012 , 7, 250-8	59
1209	Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. 2012 , 143, 910-8	76
1208	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. 2012 , 40, 214-220	1
1207	Diagnosis and mortality prediction in pulmonary hypertension: the value of the electrocardiogram-derived ventricular gradient. 2012 , 45, 312-8	13
1206	Reversal of pulmonary vascular remodeling in pulmonary hypertensive rats. 2012 , 93, 66-73	17
1205	CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension. 2012 , 62, 219-25	14
1204	Partial anomalous pulmonary venous connection and pulmonary arterial hypertension. 2012 , 17, 957-63	26
1203	BMPR2 expression is suppressed by signaling through the estrogen receptor. 2012 , 3, 6	80

1202	Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. 2012 , 64, 303-10	27
1201	An update on the evaluation and management of pulmonary hypertension in scleroderma. 2012 , 14, 1-10	5
1200	Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: Is it safe?. 2012 , 29, 271-5	7
1199	A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial. 2013 , 14, 91	20
1198	MicroRNAs in pulmonary arterial remodeling. 2013 , 70, 4479-94	52
1197	High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. 2013 , 69, 197-207	6
1196	Platelet distribution width and mean platelet volume in children with pulmonary arterial hypertension secondary to congenital heart disease with left-to-right shunt: new indices of severity?. 2013 , 34, 1013-6	14
1195	Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. 2013 , 34, 213-9	9
1194	Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. 2013 , 26, 1-14	316
1193	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. 2013 , 369, 319-29	852
1192	mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. 2013 , 27, 1796-807	49
1191	Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. 2013 , 71, 203-15	12
1190	Portopulmonary hypertension, tuberculosis and previous dirofilariasis: case report and review of literature. 2013 , 11, 101-107	1
1189	The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. 2013 , 7, 43-55	12
1188	The chemistry and biology of soluble guanylate cyclase stimulators and activators. 2013 , 52, 9442-62	147
1187	CT scanning in the evaluation of pulmonary hypertension. 2013 , 191, 321-6	13
1186	Exercise capacity affects quality of life in patients with pulmonary hypertension. 2013 , 191, 337-43	47
1185	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. 2013 , 1-20	

1184	Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). 2013 , 30, 459-71	11
1183	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. 2013 , 1, 92-101	2
1182	Current and future therapeutic targets for pulmonary arterial hypertension. 2013 , 14, 134-43	4
1181	Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension. 2013 , 8, 307-16	4
1180	World Health Organization group 5 pulmonary hypertension. 2013 , 34, 753-78	20
1179	Portopulmonary hypertension. 2013 , 34, 719-37	5
1178	Pulmonary hypertension in obstructive sleep apnea hypopnea syndrome. 2013 , 62, 459-465	6
1177	Dynamic pulmonary hypertension in decompensated heart failure with preserved ejection fraction: is functional mitral regurgitation the driver?. 2013 , 19, 753-5	
1176	Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. 2013 , 182, 2391-406	28
1175	Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. 2013 , 40, 1706-11	17
1174	Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. 2013 , 65, 2412-23	153
1173	[Multidetector computed tomography assessment of cardiac comorbidity in patients with chronic obstructive pulmonary disease]. 2013 , 55, 203-14	
1172	[Anaesthetic approach of paediatric pulmonary hypertension]. 2013 , 32, e27-30	
1171	Classification of diffuse lung diseases: why and how. 2013 , 268, 628-40	14
1170	Una mirada a la hipertensi3 pulmonar. 2013 , 48, 45-46	
1169	Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. 2013 , 29, 659-61	3
1168	Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure. 2013 , 19, 712-21	14
1167	Liver in cardiopulmonary disease. 2013 , 27, 497-512	2

1166	Causes and circumstances of death in pulmonary arterial hypertension. 2013 , 188, 365-9		138
1165	Diagnosis and treatment of pulmonary hypertension in infancy. 2013 , 89, 865-74		29
1164	Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension. 2013 , 135, 61011-15		24
1163	Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. 2013 , 188, 1126-36		46
1162	Pulmonary arterial hypertension in SLE: what do we know?. 2013 , 22, 1274-85		21
1161	Pulmonary hypertension after hematopoietic stem cell transplantation. 2013 , 19, 1546-56		57
1160	Current therapies for the treatment of pulmonary arterial hypertension. 2013 , 2-5		
1159	Pulmonary hypertension in systemic lupus erythematosus. 2013 , 27, 425-34		12
1158	Left ventricular dysfunction with pulmonary hypertension: Part 1: epidemiology, pathophysiology, and definitions. 2013 , 6, 344-54		35
1157	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D34-41	15.1	1937
1156	Pediatric pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D117-26	15.1	357
1155	Pregnancy and pulmonary hypertension: a practical approach to management. 2013 , 6, 144-54		17
1154	Management of Right Ventricular Failure in Pulmonary Hypertension (and After LVAD Implantation). 2013 , 15, 533-43		4
1153	Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation. 2013 , 16, 389-92		8
1152	Echocardiography in pediatric pulmonary hypertension. 2013 , 14, 157-64		13
1151	Drugs induced pulmonary arterial hypertension. 2013 , 42, e303-10		22
1150	Down-regulation of TRPM8 in pulmonary arteries of pulmonary hypertensive rats. 2013 , 31, 892-904		22
1149	Sildenafil zur Behandlung der pulmonalen arteriellen Hypertonie (PAH). 2013 , 161, 1029-1036		

1148	Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension. 2013 , 15, 81	49
1147	Pulmonary arterial hypertension. 2013 , 8, 97	168
1146	Pediatric pulmonary arterial hypertension. 2013 , 15, 606-13	4
1145	Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience. 2013 , 191, 593-600	30
1144	Factors associated with elevated pulmonary arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism. 2013 , 131, e191-5	8
1143	Role of curcumin in idiopathic pulmonary arterial hypertension treatment: a new therapeutic possibility. 2013 , 81, 923-6	17
1142	Echocardiographic estimation of pulmonary arterial systolic pressure in acute heart failure. Prognostic implications. 2013 , 24, 562-7	23
1141	Paediatric pulmonary hypertension and sildenafil: current practice and controversies. 2013 , 98, 141-7	23
1140	Considerations on safety and treatment of patients with chronic heart failure at high altitude. 2013 , 14, 96-100	10
1139	Utility of right ventricular strain imaging in predicting pulmonary vascular resistance in patients with pulmonary hypertension. 2013 , 19, 116-22	16
1138	The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis. 2013 , 30, 258-65	61
1137	Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension. 2013 , 43, 1016-24	16
1136	A typical case of atypical dyspnea. 2013 , 10, 261-3	1
1135	Pulmonary hypertension in dialysis patients. 2013 , 35, 514-20	23
1134	Pulmonary vascular complications of liver disease. 2013 , 187, 133-43	66
1133	Sickle cell disease, vasculopathy, and therapeutics. 2013 , 64, 451-66	79
1132	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. 2013 , 127, 1128-38	368
1131	Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel. 2013 , 107, 298-304	19

1130	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. 2013 , 32, 1114-22	74
1129	Hipertensi3 arterial pulmonar. 2013 , 11, 2625-2633	
1128	Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. 2013 , 34, 739-52	30
1127	Consensus statement for the diagnosis and treatment of drug-induced lung injuries. 2013 , 51, 260-77	130
1126	Pulmonary hypertension due to lung disease and/or hypoxia. 2013 , 34, 695-705	26
1125	The role of pulmonary vascular contractile protein expression in pulmonary arterial hypertension. 2013 , 65, 147-55	16
1124	¿C3les son los 3timos avances en hipertensi3 arterial pulmonar?. 2013 , 48, 55-59	1
1123	The Fra-2 transgenic mouse model of systemic sclerosis. 2013 , 58, 194-201	44
1122	69-year-old woman with ascites, hypoxia, and weight loss. 2013 , 88, 1475-9	
1121	Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. 2013 , 167, 1193-8	83
1120	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. 2013 , 168, 871-80	231
1119	Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension: a meta-analysis and review of the literature. 2013 , 62, 1867-75	13
1118	Pulmonary Arterial Hypertension in a Patient With Hereditary Hemorrhagic Telangiectasia. 2013 , 49, 119-121	1
1117	A practical approach to vascular pathology in pulmonary hypertension. 2013 , 19, 298-310	2
1116	Genetics of pulmonary arterial hypertension. 2013 , 34, 651-63	7
1115	A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. 2013 , 188, 756-9	37
1114	The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. 2013 , 305, L1-14	61
1113	TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. 2013 , 183, 1779-1788	31

1112	Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. 2013 , 32, 347-54	58
1111	Left ventricular diastolic dysfunction in patients with mitral stenosis undergoing percutaneous mitral balloon valvotomy. 2013 , 88, 337-44	14
1110	A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure. 2013 , 19, 50-9	10
1109	Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. 2013 , 29, 678-82	33
1108	Pulmonary arterial hypertension associated with congenital heart disease. 2013 , 34, 707-17	9
1107	Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmonary capillary hemangiomatosis. 2013 , 22, 287-93	27
1106	Inefficient exercise gas exchange identifies pulmonary hypertension in chronic thromboembolic obstruction following pulmonary embolism. 2013 , 132, 659-65	46
1105	Mujer de 66 años con disnea e inestabilidad hemodinámica. 2013 , 11, 2667.e1-2667.e4	
1104	Sleep apnea in precapillary pulmonary hypertension. 2013 , 14, 247-51	58
1103	Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. 2013 , 169, 445-8	30
1102	Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. 2013 , 111, 278-85	47
1101	Pulmonary hypertension in a patient with intravascular lymphomatosis. 2013 , 7, e181-e183	0
1100	Pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia. 2013 , 49, 119-21	7
1099	Multidetector computed tomography assessment of cardiac comorbidity in patients with chronic obstructive pulmonary disease. 2013 , 55, 203-214	
1098	Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. 2013 , 111, 1A-16A; quiz 17A-19A	48
1097	Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension. 2013 , 111, 1812-7	24
1096	High prevalence of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. 2013 , 24, e30-4	30
1095	Premature differentiation of vascular smooth muscle cells in human congenital diaphragmatic hernia. 2013 , 94, 195-202	33

1094	The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. 2013 , 44, 31-8	73
1093	The efficacy of MSC-HGF in treating pulmonary arterial hypertension (PAH) and connexin remodelling. 2013 , 8, 240-251	1
1092	Small platelet microparticle levels are increased in pulmonary arterial hypertension. 2013 , 43, 64-71	28
1091	Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension. 2013 , 14, 3	40
1090	Pulmonary hypertension in CKD. 2013 , 61, 612-22	91
1089	Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. 2013 , 143, 185-195	46
1088	Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension. 2013 , 30, 17-26	20
1087	Obesity, the Metabolic Syndrome, and Pulmonary Hypertension. 2013 , 165-182	
1086	Perspective and challenges of mesenchymal stem cells for cardiovascular regeneration. 2013 , 11, 505-17	39
1085	Role of DHEA in cardiovascular diseases. 2013 , 85, 718-26	43
1084	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. 2013 , 45, 518-21	82
1083	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. 2013 , 187, 294-302	126
1082	Methods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculature. 2013 , 41, 1384-98	52
1081	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. 2013 , 9, 335-49	26
1080	Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. 2013 , 15, 302	16
1079	Pulmonary hypertension in patients undergoing cardiac surgery: pathophysiology, perioperative management, and outcomes. 2013 , 27, 551-72	25
1078	Thrombocythémie essentielle. 2013 , 8, 1-11	
1077	Pulmonary Vascular Disease. 2013 , 603-625	1

1076	Pulmonary hypertension with extensive calcification in small pulmonary vessels and alveolar capillary wall in a chronic hemodialysis patient. 2013 , 8, e13-e16	1
1075	MicroRNA-206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1 β /Fhl-1 pathway. 2013 , 93, 748-59	52
1074	Pulmonary hypertension in β -thalassaemia. 2013 , 1, 488-96	11
1073	Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device. 2013 , 16, 101-4	13
1072	Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension. 2013 , 112, 1505-9	11
1071	A comparative study of PGI ₂ mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. 2013 , 107, 48-55	30
1070	Transforming growth factor- β signaling in schistosomiasis-induced pulmonary hypertension: a perspective for antifibrotic drugs?. 2013 , 128, 1284-5	
1069	Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. 2013 , 3,	14
1068	Cor Pulmonale. 2013 , 157-165	1
1067	Validation of the isovolumetric relaxation time for the estimation of pulmonary systolic arterial blood pressure in chronic pulmonary hypertension. 2013 , 14, 51-5	18
1066	The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease. 2013 , 124, 208-12	22
1065	Haemodynamic and structural correlates of the first and second heart sounds in pulmonary arterial hypertension: an acoustic cardiography cohort study. 2013 , 3,	11
1064	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. 2013 , 22, 543-51	126
1063	The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease. 2013 , 11, 919-31	8
1062	TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension. 2013 , 50, 500-6	115
1061	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. 2013 , 187, 189-96	42
1060	Hemodynamic predictors of mortality in adults with sickle cell disease. 2013 , 187, 840-7	98
1059	Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications. 2013 , 37, 281-90	41

1058 Hepatopulmonary syndrome and portopulmonary hypertension. **2013**, 41, 62-71

1057 Experimental models of right heart failure: a window for translational research in pulmonary hypertension. **2013**, 34, 689-99 32

1056 Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. **2013**, 305, H259-64 64

1055 Heart Transplantation in a 14-Year-Old Boy in the Presence of Severe Out-of-Proportion Pulmonary Hypertension due to Restrictive Left Heart Disease: A Case Report. **2013**, 2013, 418565 3

1054 Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. **2013**, 187, 303-10 36

1053 Pulmonary Hypertension and the Interdependence of Ventricular Function: Part 1: Pathophysiology and Diagnosis. **2013**, 4, 183-190 1

1052 Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. **2013**, 3, 369-80 37

1051 Increased pulmonary artery diameter on chest computed tomography can predict borderline pulmonary hypertension. **2013**, 3, 363-8 37

1050 Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. **2013**, 41, 1324-1330 25

1049 Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure. **2013**, 3, 916-25 42

1048 Piglet model of chronic pulmonary hypertension. **2013**, 3, 908-15 30

1047 Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review. **2013**, 3, 499-506 20

1046 Human immunodeficiency virus-1 transgene expression increases pulmonary vascular resistance and exacerbates hypoxia-induced pulmonary hypertension development. **2013**, 3, 58-67 27

1045 Current and Emerging Therapies for Pulmonary Arterial Hypertension. **2013**, 48, S7-S14

1044 Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease. **2013**, 305, L725-36 25

1043 Gender, sex hormones and pulmonary hypertension. **2013**, 3, 294-314 78

1042 Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension. **2013**, 3, 523-32 18

1041 A treatable cause of shortness of breath. **2013**, 346, f1937

1040 Clinical Overview of Pulmonary Arterial Hypertension. **2013**, 48, S1-S6

1039 Pulmonary arterial hypertension in pregnant women. **2013**, 7, 51-63 16

1038 Magnetic resonance and computed tomography imaging of the structural and functional changes of pulmonary arterial hypertension. **2013**, 28, 178-93 18

1037 Pulmonary hypertension survival effects and treatment options in cystic fibrosis. **2013**, 19, 652-61 18

1036 SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension. **2013**, 61, 1044-52 30

1035 Pulmonary arterial hypertension: challenges in translational research and a vision for change. **2013**, 5, 208sr5 60

1034 Pathology and diagnosis of pulmonary arterial hypertension. **2013**, 24-39

1033 Combination pharmacotherapy in the treatment of pulmonary arterial hypertension: continuing education article. **2013**, 26, 18-28 2

1032 Scleroderma lung disease. **2013**, 22, 6-19 158

1031 Perioperative Management of the Patient with Pulmonary Hypertension. **2013**, 137-154 1

1030 Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. **2013**, 49, 403-9 81

1029 Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. **2013**, 85, 471-7 19

1028 A potential role for insulin resistance in experimental pulmonary hypertension. **2013**, 41, 861-71 87

1027 Wrist actigraphy predicts outcome in patients with pulmonary hypertension. **2013**, 86, 45-51 29

1026 Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension. **2013**, 85, 355-64 13

1025 Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. **2013**, 6, 711-21 256

1024 Role of imaging in the diagnosis and management of parasitic infections. **2013**, 19, 310-7 3

1023 Human immunodeficiency virus and pulmonary arterial hypertension. **2013**, 2013, 903454 8

1022	Pulmonary hypertension in Portugal: first data from a nationwide registry. 2013 , 2013, 489574	34
1021	Pericardial effusion in pulmonary arterial hypertension. 2013 , 3, 467-77	26
1020	Pulmonary hypertension: Another light in the dark tunnel. Learning the lesson from cancer. 2013 , 8, 69-70	9
1019	Pulmonary hypertension in Saudi Arabia: A single center experience. 2013 , 8, 78-85	18
1018	Regulation of ca(2+) signaling in pulmonary hypertension. 2013 , 17, 1-8	15
1017	Spleen size in idiopathic and heritable pulmonary arterial hypertension. 2013 , 85, 391-9	6
1016	Acute hemodynamic responses to supplemental oxygen and their prognostic implications in pulmonary hypertension. 2013 , 85, 400-7	9
1015	Current challenges in pediatric pulmonary hypertension. 2013 , 34, 627-44	18
1014	Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes. 2013 , 3, 5-19	37
1013	Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. 2013 , 3, 144-52	118
1012	Heritable forms of pulmonary arterial hypertension. 2013 , 34, 568-80	19
1011	Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. 2013 , 18, 1271-7	24
1010	Geometry of the randomized evidence for treatments of pulmonary hypertension. 2013 , 31, e138-46	14
1009	Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. 2013 , 43, 855-65	71
1008	Value of impedance cardiography during 6-minute walk test in pulmonary hypertension. 2013 , 6, 474-80	11
1007	Pulmonary hypertension in patients with chronic and end-stage kidney disease. 2013 , 84, 682-92	74
1006	The transforming growth factor- β -bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. 2013 , 98, 1262-6	37
1005	Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. 2013 , 15, 771-5	80

1004	Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. 2013 , 15, 433-40	66
1003	Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases. 2013 , 3, 1749-79	15
1002	Combination therapy in the management of pulmonary arterial hypertension. 2013 , 67, 13-23	16
1001	Qualitative echocardiography parameters for prediction of pulmonary hypertension. 2013 , 67, 5-12	7
1000	A virtual community: concerns of patients with pulmonary hypertension. 2013 , 22, 155-71	18
999	A new computational framework for anatomically consistent 3D statistical shape analysis with clinical imaging applications. 2013 , 1, 13-27	4
998	Advances in the Management of Pulmonary Arterial Hypertension. 2013 ,	
997	Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. 2013 , 304, H1708-18	76
996	Reactive oxygen species as therapeutic targets in pulmonary hypertension. 2013 , 7, 175-200	40
995	Right ventricular failure. 2013 , 112-121	
994	[Enhanced Ca ²⁺ -sensing receptor function in pulmonary hypertension]. 2013 , 133, 1351-9	7
993	Drastic shift from positive to negative estrogen effect on bone morphogenetic protein signaling in pulmonary arterial endothelial cells under hypoxia. 2013 , 77, 2118-26	8
992	Optical coherence tomography is superior to intravascular ultrasound for diagnosis of distal-type chronic thromboembolic pulmonary hypertension. 2013 , 77, 1081-3	31
991	Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. 2013 , 77, 2619-25	114
990	Surgical management of chronic thromboembolic pulmonary hypertension. 2013 , 74, 31-5	8
989	Management of chronic thromboembolic pulmonary hypertension: current status and emerging options. 2013 , 10, 345-357	2
988	Nicorandil inhibits hypoxia-induced apoptosis in human pulmonary artery endothelial cells through activation of mitoKATP and regulation of eNOS and the NF- κ B pathway. 2013 , 32, 187-94	15
987	Practical recommendations on the use of echocardiography to assess pulmonary arterial hypertension--a Belgian expert consensus endorsed by the Working Group on Non-Invasive Cardiac Imaging. 2013 , 68, 59-69	9

986 Stimulators and activators of soluble guanylate cyclase: potential therapeutic indications. **2013**, 74-87

985 Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. **2013**, 144, 1530-1538 60

984 Counterpoint: can Doppler echocardiography estimates of pulmonary artery systolic pressures be relied upon to accurately make the diagnosis of pulmonary hypertension? No. **2013**, 143, 1536-1539 27

983 Chronic pulmonary emboli and radiologic mimics on CT pulmonary angiography: a diagnostic challenge. **2013**, 143, 1460-1471 29

982 Chemie und Biologie der Stimulatoren und Aktivatoren der löslichen Guanylatcyclase. **2013**, 125, 9618-9639 3

981 Endothelial progenitor cell-based therapy for pulmonary arterial hypertension. **2013**, 22, 1325-36 15

980 Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. **2013**, 143, 758-766 266

979 Systemic sclerosis-associated pulmonary arterial hypertension. **2013**, 144, 1346-1356 92

978 WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension. **2013**, 144, 638-650 36

977 Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. **2013**, 144, 169-176 86

976 A pathophysiological approach towards right ventricular function and failure. **2013**, 30, 386-94 9

975 Endoglin: a critical mediator of cardiovascular health. **2013**, 9, 195-206 37

974 Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. **2013**, 98, 1359-67 35

973 Conventional therapy. **2013**, 40-50

972 Anticoagulation therapy versus placebo for pulmonary hypertension. **2013**,

971 [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 1. Pulmonary hypertension associated with connective tissue diseases]. **2013**, 102, 2613-20

970 Spontaneously remitted pulmonary arterial hypertension associated with the herbal medicine "bofutsushosan". **2013**, 52, 1499-502 2

969 A Case of Pulmonary Hypertension Recurred by Graves' Disease. **2013**, 28, 171

- 968 Partial Anomalous Pulmonary Venous Return (PAPVR) in a Patient with Sjogren's Syndrome. **2013**, 20, 266
- 967 Pulmonary arterial hypertension: diagnosis and treatment. **2013**, 3, 273-279
- 966 MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. **2013**, 19, 1-16 2
- 965 Cardiopulmonary Disease in SLE. **2013**, 352-362
- 964 Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension. **2013**, 8, e73502 14
- 963 [Pulmonary arterial hypertension: a flavor of autoimmunity]. **2013**, 29, 607-16 4
- 962 Targeted therapies: endothelin receptor antagonists. **2013**, 64-73
- 961 Pulmonary Arterial Hypertension. **2013**, 667-686 4
- 960 Pulmonary Arterial Hypertension: An Overview. **2013**,
- 959 Pulmonary veno-occlusive disease: an uncommon cause of pulmonary hypertension. **2013**, 2013, 6
- 958 Clinical Manifestations of Sarcoidosis. **2013**,
- 957 Pathogenesis of Pulmonary Hypertension. **2013**,
- 956 Pulmonary Hypertension/Pulmonary Arterial Hypertension. **2014**, 2625-2635
- 955 Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension. **2014**, 55, 1526-32 10
- 954 CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit+ cells in rats. **2014**, 9, e89810 32
- 953 Usefulness of decrease in oxygen uptake efficiency to identify gas exchange abnormality in patients with idiopathic pulmonary arterial hypertension. **2014**, 9, e98889 13
- 952 HMGB1 promotes the development of pulmonary arterial hypertension in rats. **2014**, 9, e102482 40
- 951 Utility of the physical examination in detecting pulmonary hypertension. A mixed methods study. **2014**, 9, e108499 18

950	Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidity. 2014 , 9, e114392	19
949	The flavonoid quercetin reverses pulmonary hypertension in rats. 2014 , 9, e114492	52
948	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. 2015 , 66, 270-6	11
947	Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease. 2014 , 4,	31
946	Pulmonary Arterial Hypertension and Insulin Resistance. 2014 , 2,	5
945	Clinical characteristics and survival of Korean idiopathic pulmonary arterial hypertension patients based on vasoreactivity. 2014 , 29, 1665-71	2
944	A case of pulmonary arterial hypertension associated with congenital extrahepatic portocaval shunt. 2014 , 29, 604-8	7
943	Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. 2014 , 37, 196-201	43
942	Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. 2014 , 28, 25-39	65
941	Pulmonary Hypertension. 2014 ,	
940	Pathological function of Ca ²⁺ -sensing receptor in pulmonary arterial hypertension. 2014 , 50, 8-17	21
939	Pulmonary Hypertension Associated with Respiratory Diseases. 2014 , 1-25	
938	Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. 2014 , 189, 1110-20	14
937	Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. 2014 , 8, 71-77	11
936	Development of a UPLC-MS/MS method for the quantification of sildenafil by DBS, and its use on pediatric pulmonary hypertension. 2014 , 6, 2815-24	6
935	Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats. 2014 , 306, H243-50	58
934	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension. 2014 , 9, S98-S107	12
933	Noninvasive imaging of pulmonary hypertension. 2014 , 35, 99-111	10

932	CCR5 as a treatment target in pulmonary arterial hypertension. 2014 , 130, 880-891	49
931	Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series). 2014 , 4, 353-62	17
930	Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. 2014 , 2014, 617565	9
929	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. 2014 , 44, 1069-72	33
928	Lung capillary injury and repair in left heart disease: a new target for therapy?. 2014 , 127, 65-76	17
927	Reversible pre-capillary pulmonary hypertension due to dasatinib. 2014 , 59, e77-80	8
926	The effect of male sex on survival in systemic sclerosis. 2014 , 41, 2193-200	40
925	Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis. 2014 , 35, 362-71	31
924	Pulmonary arterial hypertension in a patient with Cowden syndrome and the PTEN mutation. 2014 , 4, 728-31	6
923	Pulmonary Manifestations of Systemic Lupus Erythematosus (SLE). 2014 , 61-72	2
922	Measuring health in pulmonary hypertension: emphasising the right end-point?. 2014 , 43, 960-2	1
921	Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. 2014 , 145, 810-817	104
920	Anticoagulation therapy versus placebo for pulmonary hypertension. 2014 , CD010695	6
919	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. 2014 , 146, 1494-1504	94
918	Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. 2014 , 4, 311-8	40
917	Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans. 2014 , 93, 177-185	21
916	Pulmonary Hypertension. 2014 , 426-432	
915	Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. 2014 , 44, 331-7	32

914	Chronic thromboembolic pulmonary hypertension (CTEPH) - potential role of multidetector-row CT (MD-CT) and MR imaging in the diagnosis and differential diagnosis of the disease. 2014 , 186, 751-61	14
913	Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERRA). 2014 , 129, 57-65	235
912	Mutations of NOTCH3 in childhood pulmonary arterial hypertension. 2014 , 2, 229-39	37
911	Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. 2014 , 171, 567-79	62
910	Pulmonary arterial hypertension associated with the use of interferon therapy for chronic hepatitis C infection complicated by extrinsic left main coronary artery compression. 2014 , 44, 1027-30	6
909	Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis. 2014 , 19, 269-275	19
908	Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways. 2014 , 63, 309-15	24
907	Objective measures of right ventricular function during exercise: results of a pilot study. 2014 , 31, 508-15	7
906	Selectins and platelet-derived growth factor (PDGF) in schistosomiasis-associated pulmonary hypertension. 2014 , 192, 981-6	7
905	Septal curvature is marker of hemodynamic, anatomical, and electromechanical ventricular interdependence in patients with pulmonary arterial hypertension. 2014 , 31, 699-707	49
904	Six-minute walk distance target in elderly patients with idiopathic pulmonary arterial hypertension - consideration of predicted values. 2014 , 68, 543-50	2
903	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. 2014 , 306, L986-95	25
902	Subcellular distribution patterns and elevated expression of GNA11 and GNA14 proteins in the lungs of humans with pulmonary arterial hypertension. 2014 , 38, 1041-9	4
901	Pulmonary veno-occlusive disease: an 80-year-old mystery. 2014 , 88, 148-57	7
900	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. 2014 , 44, 1275-88	135
899	Remodeling of the pulmonary artery induced by metastatic gastric carcinoma: a histopathological analysis of 51 autopsy cases. 2014 , 14, 14	11
898	Non specific pattern of lung function in a respiratory physiology unit: causes and prevalence: results of an observational cross-sectional and longitudinal study. 2014 , 14, 148	13
897	High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. 2014 , 7, 116-22	123

- 896 Improving outcomes for pulmonary hypertension. **2014**, 9, 32-40
- 895 Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the art. **2014**, 29, 68-79 49
- 894 Update on scleroderma and other fibrosing syndromes. **2014**, 26, 605-6
- 893 Sublingual microcirculation in pulmonary arterial hypertension. **2014**, 11, 504-12 27
- 892 Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?. **2014**, 23, 458-68 9
- 891 Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. **2014**, 29, 178-84 36
- 890 Progress in the diagnosis and management of pulmonary hypertension in children. **2014**, 26, 527-35 11
- 889 Genetics of pulmonary hypertension. **2014**, 29, 520-7 31
- 888 Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. **2014**, 259, 123-30 95
- 887 Pharmacologic management of perioperative pulmonary hypertension. **2014**, 63, 375-84 8
- 886 Pulmonary arterial hypertension in patients treated with interferon. **2014**, 44, 1627-34 66
- 885 Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. **2014**, 7, 107-14 111
- 884 Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. **2014**, 9, S67-73 7
- 883 Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. **2014**, 55, 223-5 17
- 882 Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. **2014**, 44, 425-34 48
- 881 Pulmonary hypertension after pneumonectomy for lung cancer. **2014**, 22, 1072-9 11
- 880 Trends in pulmonary hypertension mortality and morbidity. **2014**, 2014, 105864 23
- 879 Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. **2014**, 88, 38-45 14

878	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia. 2014 , 9, S56-61	6
877	The role of endothelin-1 in pulmonary arterial hypertension. 2014 , 2014, 62-78	66
876	Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease. 2014 , 4, 319-29	7
875	Noninvasive imaging for the diagnosis and prognosis of pulmonary hypertension. 2014 , 12, 71-86	7
874	Non-invasive assessment of cardiac function and pulmonary vascular resistance in an canine model of acute thromboembolic pulmonary hypertension using 4D flow cardiovascular magnetic resonance. 2014 , 16, 23	22
873	Prognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy. 2014 , 27, 733-741.e2	23
872	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. 2014 , 44, 55-62	56
871	Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. 2014 , 30, 879-87	21
870	Pulmonary hypertension in young adults with repaired coarctation of the aorta: an unrecognised factor associated with premature mortality and heart failure. 2014 , 174, 324-9	10
869	Utility of electrocardiogram in the assessment and monitoring of pulmonary hypertension (idiopathic or secondary to pulmonary developmental abnormalities) in patients ≥18 years of age. 2014 , 114, 294-9	8
868	Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2882-3	15.1 3
867	Portopulmonary hypertension. 2014 , 18, 421-38	37
866	Effect of sildenafil in the management of preoperative pulmonary hypertensionAvailable online 22 June 2013View all notesPeer review under responsibility of Alexandria University Faculty of Medicine.View all notes. 2014 , 50, 13-16	0
865	Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension. 2014 , 28, 26-33	10
864	Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients. 2014 , 46, 141-9	31
863	The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. 2014 , 192, 321-8	46
862	Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. 2014 , 35, 699-704	23
861	Pulmonary hypertension in systemic lupus erythematosus: echocardiography-based definitions predict 6-year survival. 2014 , 53, 1256-63	19

860	Macitentan for the treatment of pulmonary arterial hypertension. 2014 , 48, 538-47	15
859	Cellular interplay in pulmonary arterial hypertension: implications for new therapies. 2014 , 1843, 885-93	21
858	Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort. 2014 , 33, 197-205	10
857	Safety and tolerability of targeted therapies for pulmonary hypertension in children. 2014 , 35, 490-8	15
856	Pulmonary Hypertension and Thoracic Surgery: Diagnostics and Advances in Therapy and Intraoperative Management. 2014 , 4, 135-141	4
855	Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study. 2014 , 24, 668-76	18
854	Drug treatment of pulmonary hypertension in children. 2014 , 16, 43-65	32
853	Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. 2014 , 108, 531-7	29
852	Pulmonary hypertension and noncardiac surgery: implications for the anesthesiologist. 2014 , 28, 1064-74	16
851	Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes. 2014 , 70, 13-21	10
850	Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2159-2169	15.1 90
849	Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. 2014 , 52, 167-72	4
848	HIF and pulmonary vascular responses to hypoxia. 2014 , 116, 867-74	66
847	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. 2014 , 46, 65-9	259
846	Dfaillance cardiaque dans l'hypertension artérielle pulmonaire idiopathique: les pièges à éviter. 2014 , 23, 352-365	1
845	Pulmonary arterial hypertension related to connective tissue disease: a review. 2014 , 40, 103-24	26
844	Targeted therapies in pulmonary arterial hypertension. 2014 , 141, 172-91	128
843	Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. 2014 , 68, 90-8	26

842	Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. 2014 , 33, 12-9	29
841	Prevalence and risk factors for pulmonary arterial hypertension in a large group of β -thalassemia patients using right heart catheterization: a Webthal study. 2014 , 129, 338-45	79
840	Clinical diagnosis of pulmonary hypertension. 2014 , 130, 1820-30	79
839	Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. 2014 , 66, 1900-8	34
838	Right ventricular function in heart failure with preserved ejection fraction: a community-based study. 2014 , 130, 2310-20	295
837	Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. 2014 , 13, 391-405	51
836	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. 2014 , 73, 1340-9	444
835	Pulmonary hypertension in cystic fibrosis with advanced lung disease. 2014 , 190, 898-905	50
834	Clinical implications of the hyperdynamic syndrome in cirrhosis. 2014 , 25, 795-802	33
833	An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis. 2014 , 10, 732-40	14
832	Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. 2014 , 114, 1420-5	33
831	Perioperative management of pulmonary hypertension during lung transplantation (a lesson for other anaesthesia settings). 2014 , 61, 434-45	5
830	Perioperative management of the patient with pulmonary hypertension. 2014 , 18, 310-8	18
829	Pulmonary endarterectomy: part I. Pathophysiology, clinical manifestations, and diagnostic evaluation of chronic thromboembolic pulmonary hypertension. 2014 , 18, 319-30	33
828	Molecular imaging of the pulmonary circulation in health and disease. 2014 , 2, 415-426	8
827	Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling. 2014 , 307, L317-25	42
826	Pulmonary Hypertension. 2014 , 189-200	
825	Enhanced [18 F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long-term prognosis of patients with pulmonary hypertension: a preliminary observational study. 2014 , 15, 666-72	47

824	Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of right ventricular dysfunction in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 41-51	15.1	143
823	An implementation of independent component analysis for 3D statistical shape analysis. 2014 , 13, 345-356		10
822	Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. 2014 , 48, 223-33		15
821	Update in systemic sclerosis-associated pulmonary arterial hypertension. 2014 , 43, e293-304		20
820	Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. 2014 , 190, 808-17		129
819	The genetics of pulmonary arterial hypertension. 2014 , 115, 189-202		116
818	Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity. 2014 , 306, H15-25		41
817	Development and pathologies of the arterial wall. 2014 , 71, 1977-99		20
816	[Cor pulmonale and pulmonary hypertension. Update after the world conference in Nice]. 2014 , 39, 58-65		1
815	Polysomnographic differences associated with pulmonary hypertension in patients with advanced lung disease due to cystic fibrosis. 2014 , 192, 413-9		4
814	Heat stress is associated with reduced health status in pulmonary arterial hypertension: a prospective study cohort. 2014 , 192, 619-24		14
813	Prognostic significance of dilated inferior vena cava in advanced decompensated heart failure. 2014 , 30, 1289-95		15
812	Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure. 2014 , 19, 781-8		13
811	Accuracy of chest radiography in predicting pulmonary hypertension: a case-control study. 2014 , 133, 345-51		10
810	The exceptional and far-flung manifestations of heart failure in Eisenmenger syndrome. 2014 , 10, 91-104		12
809	Pulmonary arterial hypertension in HIV infection: a concise review. 2014 , 23, 299-302		7
808	Sex differences in the pulmonary circulation: implications for pulmonary hypertension. 2014 , 306, H1253-64		24
807	Pulmonary hypertension in adult congenital heart disease. 2014 , 16, 328		2

806	Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. 2014 , 35, 716-24	174
805	The minimally invasive MitraClip procedure for mitral regurgitation under general anaesthesia: immediate effects on the pulmonary circulation and right ventricular function. 2014 , 69, 860-7	15
804	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. 2014 , 129, 1332-40	110
803	Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. 2014 , 34, 2486-94	46
802	[Patterns of pulmonary vascularization on plain-film chest X-rays]. 2014 , 56, 346-56	
801	Echocardiography versus right heart catheterization in class I pulmonary hypertension. 2014 , 63, 419-422	3
800	Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. 2014 , 43, 256-61	6
799	The metabolic basis of pulmonary arterial hypertension. 2014 , 19, 558-73	149
798	CD4+ T cells and IFN- γ are required for the development of Pneumocystis-associated pulmonary hypertension. 2014 , 184, 483-93	8
797	Prognostic significance of six-minute walk test in non-group 1 pulmonary hypertension. 2014 , 43, 72-6	12
796	Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. 2014 , 13, 416-23	20
795	Sudden, unexpected infant death due to pulmonary arterial hypertension. 2014 , 16, 44-7	1
794	Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO ₂ . 2014 , 118, 397-403	9
793	CT-based pulmonary artery measurements for the assessment of pulmonary hypertension. 2014 , 21, 523-30	50
792	Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy. 2014 , 2, 230-7	18
791	Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments. 2014 , 2, 1137-1145	2
790	Pulmonary arterial hypertension in pregnancy. 2014 , 38, 289-94	23
789	Orphan drugs and rare diseases: a scientometric review (2000-2014). 2014 , 2, 709-724	105

788	Case records of the Massachusetts General Hospital. Case 9-2014. A 34-year-old woman with increasing dyspnea. 2014 , 370, 1149-57	4
787	Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. 2014 , 175, 268-73	11
786	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. 2014 , 8, 84-92	7
785	The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. 2014 , 115, 176-88	264
784	An official American Thoracic Society Statement: pulmonary hypertension phenotypes. 2014 , 189, 345-55	60
783	Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. 2014 , 35, 369-89	53
782	Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). 2014 , 113, 147-55	73
781	Pulmonary arterial hypertension associated with IgG4-related disease. 2014 , 53, 493-7	15
780	Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists. 2014 , 53, 771-5	4
779	[Role of the Rho-kinase pathway in pulmonary arterial hypertension]. 2014 , 143, 178-81	4
778	Cardiovascular system. 63-77	
777	Pulmonary hypertensive crisis. 69-71	
776	Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. 2014 , 4, e005950	30
775	Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). 2014 , 4, 237-43	20
774	Use of pulmonary arterial hypertension-specific therapy in overweight or obese patients with obstructive sleep apnea and pulmonary hypertension. 2014 , 4, 244-9	2
773	Prognostic value of pulmonary hypertension in ambulatory patients with non-ischemic dilated cardiomyopathy. 2014 , 78, 1245-53	15
772	Visualization of complete regression of pulmonary arterial remodeling on optical coherence tomography in a patient with pulmonary arterial hypertension. 2014 , 78, 2771-3	7
771	Patient Selection and Indications for Lung Transplantation. 2014 , 388-403	

770	Pulmonary hypertension detection using dynamic and static measurable parameters on CT angiography. 2014 , 38, 586-90	6
769	Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). 2014 , 4, 330-41	33
768	Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease. 2014 , 146, e81-e83	9
767	Pulmonary hypertension surveillance: United States, 2001 to 2010. 2014 , 146, 476-495	82
766	Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using the conductance catheter. 2014 , 116, 355-63	68
765	EIF2AK4 mutations in pulmonary capillary hemangiomatosis. 2014 , 145, 231-236	143
764	Parasites of the air passages. 2014 , 145, 883-895	13
763	Pulmonary capillary hemangiomatosis: the puzzle takes shape. 2014 , 145, 197-199	13
762	Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. 2014 , 146, 686-708	37
761	Causes of pulmonary hypertension in the elderly. 2014 , 146, 159-166	39
760	Pulmonary vascular changes 22 years after single lung transplantation for pulmonary arterial hypertension: a case report with molecular and pathological analysis. 2015 , 5, 739-43	3
759	An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR. 2015 , 5, 15100	60
758	Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension. 2015 , 11, 2631-43	27
757	Ankylosing spondylitis associated with pulmonary arterial hypertension. 2015 , 54, 431-4	2
756	Effects of ambient hydrostatic pressure on the material properties of the encapsulation of an ultrasound contrast microbubble. 2015 , 138, 624-34	8
755	Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet. 2015 , e53133	6
754	Current Treatment Strategies in Pulmonary Hypertension Associated with Left Heart Disease. 2015 , 2, 345-354	1
753	K198N polymorphism in the EDN1 gene in patients with pulmonary arterial hypertension. 2015 , 144, 348-352	1

- 752 Central Nervous System and Pulmonary Complications of End-Stage Liver Disease. **2015**, 2107-2128
- 751 Calcium channel blockers for pulmonary arterial hypertension. **2015**, CD010066 6
- 750 Pulmonary arterial wall thickness in Eisenmenger Syndrome: Prospective, cross-sectional, controlled clinical trial. **2015**, 50, 1253-61 2
- 749 Melatonin as a preventive and curative therapy against pulmonary hypertension. **2015**, 59, 343-53 45
- 748 Care of the patient with pulmonary arterial hypertension. **2015**, 34, 340-7
- 747 Meeting report of the 2014 joint international congress of the International Liver Transplantation Society, Liver Intensive Care Group of Europe, and European Liver and Intestinal Association. **2015**, 21, 991-1000
- 746 DCCN on the Web. **2015**, 34, 347
- 745 Pulmonary hypertension in sickle cell disease. **2015**, 21, 432-7 7
- 744 Cambios agudos en la funci3n auricular derecha post uso de iloprost inhalatorio en pacientes con hipertensi3n arterial pulmonar: estudio con t3cnicas de deformaci3n de imagen. **2015**, 34, 100-105
- 743 Pulmonary Hypertension and Exercise Training: Evidence Based Studies. **2015**, 01,
- 742 Prevalence of Congenital Heart Disease and Pulmonary Hypertension in Down's Syndrome: An Echocardiographic Study. **2015**, 23, 72-7 28
- 741 Variants of PGIS and PPARγ in Idiopathic Pulmonary Arterial Hypertension. **2015**, 3,
- 740 Early Effects of Oral Pulmonary Vasodilators in an Elderly Patient with Critical Thromboembolic Pulmonary Hypertension: A Case Report. **2015**, 82, 206-10
- 739 Sarcoidosis and the heart: A review of the literature. **2015**, 4, 170-80 31
- 738 Pulmonary arterial hypertension associated with tetralogy of Fallot. **2015**, 56 Suppl, S17-21 12
- 737 Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension. **2015**, 22, 42-6 17
- 736 Modulation of miRNAs in Pulmonary Hypertension. **2015**, 2015, 169069 24
- 735 The right ventricle in scleroderma (2013 Grover Conference Series). **2015**, 5, 3-14 16

734	Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle. 2015 , 5, 244-68	24
733	Management of Crashing Patients with Pulmonary Hypertension. 2015 , 33, 623-43	2
732	Pulmonary hypertension in patients undergoing transcatheter aortic valve replacement: discussion of the current evidence. 2015 , 8, e002253	2
731	Perioperative Anesthesia Management in Secondary Mitral Regurgitation and Heart Failure. 2015 , 73-95	
730	Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. 2015 , 8, 627-38	26
729	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. 2015 , 15, 62	3
728	Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2015 , 41, 489-506	8
727	Echocardiographic and Hemodynamic Predictors of Survival in Precapillary Pulmonary Hypertension: Seven-Year Follow-Up. 2015 , 8,	32
726	Na(+)/H(+) exchange and hypoxic pulmonary hypertension. 2015 , 5, 228-43	14
725	Approaching atrial septal defects in pulmonary hypertension. 2015 , 13, 693-701	13
724	Conjunctival and pulmonary hemodynamic properties in sickle cell disease subjects with and without pulmonary hypertension. 2015 , 3, 1038-41	2
723	microRNA: Medical Evidence. 2015 ,	14
722	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. 2015 , 132, 2037-99	624
721	microRNA and Pulmonary Hypertension. 2015 , 888, 237-52	47
720	Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. 2015 , 147, 198-208	60
719	Dose-dependent, therapeutic potential of angiotensin-(1-7) for the treatment of pulmonary arterial hypertension. 2015 , 5, 649-57	21
718	Profiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension. 2015 , 5, 667-80	12
717	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. 2015 , 34, 1366-75	72

716	Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. 2015 , 90, 220-8	19
715	Characterization of pulmonary hypertension in heart failure using the diastolic pressure gradient: limitations of a solitary measurement. 2015 , 3, 17-21	27
714	Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. 2015 , 45, 139-49	32
713	"Porto-pulmonary hypertension: a comprehensive review". 2015 , 39, 157-67	19
712	Long-term data from the Swiss pulmonary hypertension registry. 2015 , 89, 127-40	54
711	Proteomics of pulmonary hypertension: could personalized profiles lead to personalized medicine?. 2015 , 9, 111-20	9
710	A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System. 2015 , 31, 367-74	12
709	Pulmonary Hypertension in CKD: A New Problem Child. 2015 , 153-162	
708	Portopulmonary hypertension. 2015 , 212-224	
707	Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. 2015 , 131, 401-9; discussion 409	60
706	Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. 2015 , 17, 151-8	32
705	Endothelial-to-mesenchymal transition in pulmonary hypertension. 2015 , 131, 1006-18	320
704	Influence of pulmonary hypertension on survival in advanced lung disease. 2015 , 193, 213-21	10
703	The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. 2015 , 61, 129-37	43
702	High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. 2015 , 88, 130-6	26
701	A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. 2015 , 88, 579-83	45
700	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. 2015 , 5, 356-63	32
699	Trends in Hospitalization for Pediatric Pulmonary Hypertension. 2015 , 136, 241-50	32

698	Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons. 2015 , 82, 1128-34	1
697	Left and Right Ventricular Functional Dynamics Determined by Echocardiograms Before and After Lung Transplantation. 2015 , 116, 652-9	3
696	Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. 2015 , 56, 45-51	14
695	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. 2015 , 34, 348-55	11
694	Beta blocker for patients with pulmonary arterial hypertension: A single center experience. 2015 , 184, 528-532	8
693	To decipher the hypoxic pulmonary hypertension: Vascular heterogeneity and the hypothesis of hypoxic responsive threshold. 2015 , 9, 29-37	
692	Schistosomiasis-Associated Pulmonary Arterial Hypertension. 2015 , 143-163	
691	Pulmonary hypertension is closely related to arterial stiffness in renal transplant patients. 2015 , 47, 1186-9	6
690	Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. 2015 , 5, 211-6	5
689	Epidemiology and Disease Classification of Pulmonary Hypertension. 2015 , 21-35	1
688	Pulmonary capillary hemangiomatosis: a rare cause of pulmonary hypertension. 2015 , 139, 274-7	36
687	Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. 2015 , 5, 364-9	23
686	Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. 2015 , 5, 296-304	26
685	Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy. 2015 , 42, 50-4	1
684	Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009. 2015 , 5, 339-48	28
683	Arginine metabolic endotypes in pulmonary arterial hypertension. 2015 , 5, 124-34	32
682	TRP Channels in Cardiovascular Disease. 2015 , 365-383	0
681	Efectos beneficiosos de la simpatectomía renal sobre el remodelado vascular pulmonar en la hipertensión arterial primaria experimental. 2015 , 68, 562-570	15

680	Beneficial Effects of Renal Denervation on Pulmonary Vascular Remodeling in Experimental Pulmonary Artery Hypertension. 2015 , 68, 562-70	10
679	Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. 2015 , 34, 312-8	11
678	A combination of two novel alpha globin variants Hb Bridlington (HBA1) and Hb Taybe (HBA2) resulting in severe hemolysis, pulmonary hypertension, and death. 2015 , 20, 50-2	5
677	Portopulmonary Hypertension and Hepatopulmonary Syndrome. 2015 , 514-534	1
676	Pulmonary Artery Pathology. 2015 , 31-52	
675	Right ventricular wave reflection relate to clinical measures in pulmonary arterial hypertension. 2015 , 49, 235-9	1
674	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. 2015 , 169, 806-12	25
673	Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling. 2015 , 191, 850-4	17
672	Featured Article: microRNA-125a in pulmonary hypertension: Regulator of a proliferative phenotype of endothelial cells. 2015 , 240, 1580-9	24
671	Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressure. 2015 , 25, 744-7	2
670	Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. 2015 , 24, 272-82	37
669	Association of Pulmonary Hypertension with Mortality in Incident Peritoneal Dialysis Patients. 2015 , 35, 537-44	17
668	The pathophysiology of pulmonary hypertension in left heart disease. 2015 , 309, L924-41	40
667	Encyclopedia of Trauma Care. 2015 , 1355-1356	
666	Encyclopedia of Trauma Care. 2015 , 1166-1175	
665	Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. 2015 , 35, 353-61	9
664	Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. 2015 , 20, 481-7	11
663	The Pathophysiology, Presentation and Diagnostic Investigation of Pulmonary Hypertension. 2015 , 1-35	1

662	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	1672
661	Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome. 2015 , 10, 149-160	1
660	Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Prevalence and Hemodynamic Differences in Lung Transplant Recipients at Transplant Center's Referral Time. 2015 , 47, 2161-5	11
659	Encyclopedia of Trauma Care. 2015 , 1181-1192	
658	Encyclopedia of Trauma Care. 2015 , 1304-1308	
657	Serotonin transporter is not required for the development of severe pulmonary hypertension in the Sugen hypoxia rat model. 2015 , 309, L1164-73	11
656	Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. 2015 , 192, 219-28	63
655	Is dasatinib-related pulmonary hypertension a clinical concern?. 2015 , 11, 2491-4	1
654	A case of diffuse panbronchiolitis, associated with severe pulmonary hypertension, managed with bilateral lung transplantation from a brain-dead donor. 2015 , 53, 242-6	3
653	Effects of captopril on cardiovascular reflexes and respiratory mechanisms in rats submitted to monocrotaline-induced pulmonary arterial hypertension. 2015 , 30, 57-65	6
652	New predictors of mortality in adults with congenital heart disease and pulmonary hypertension: Midterm outcome of a prospective study. 2015 , 181, 270-6	29
651	Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. 2015 , 104, 197-207	35
650	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). 2015 , 45, 1293-302	175
649	A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF- β cascades with restored caveolin-1 expression. 2015 , 41, 21-31	32
648	Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease. 2015 , 593, 3815-28	51
647	Pulmonary hypertension management in neonates. 2015 , 24, 12-6	6
646	Effects of exercise and vasodilators on cerebral tissue oxygenation in pulmonary hypertension. 2015 , 193, 113-20	16
645	Early detection of pulmonary arterial hypertension. 2015 , 12, 143-55	84

644	[K198N polymorphism in the EDN1 gene in patients with pulmonary arterial hypertension]. 2015 , 144, 348-52	4
643	NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress. 2015 , 23, 375-405	41
642	Computational models for patient-specific analysis of pulmonary vascular disease. 2015 , 15, 29-36	1
641	Pulmonary arterial systolic pressure and E/e' in the evaluation of left ventricular filling pressure: assessment of patients with atrial fibrillation. 2015 , 40, 298-303	7
640	Diagnostic dilemma in pulmonary arterial hypertension: idiopathic or chronic thromboembolic hypertension?. 2015 , 40, 338-9	
639	Use of inhaled iloprost in children with pulmonary hypertension. 2015 , 50, 370-9	5
638	Pulmonary hypertension associates with malnutrition and body composition hemodialysis patients. 2015 , 37, 273-9	7
637	Current trends in preoperative, intraoperative, and postoperative care of the adult cardiac surgery patient. 2015 , 52, 531-69	30
636	Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 2015 , 39, 139-43	4
635	Portopulmonary Hypertension. 2016 ,	
634	Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. 2016 , 24, 312-316	7
633	HRCT diagnosis of combined pulmonary fibrosis and emphysema in a patient of chronic obstructive pulmonary disease with pulmonary hypertension and clinical or radiograph suspicion of pulmonary fibrosis. 2016 , 2, 20150070	
632	Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension. 2016 , 57, 234-40	17
631	Low WSS and High OSI Measured by 3D Cine PC MRI Reflect High Pulmonary Artery Pressures in Suspected Secondary Pulmonary Arterial Hypertension. 2016 , 15, 193-202	15
630	Decompensated Heart Failure in Pregnancy. 2016 , 2, 20-26	16
629	Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease. 2016 , 2016, 3837182	1
628	New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension. 2016 , 22, S3-21	11
627	Patent ductus arteriosus with persistent pulmonary artery hypertension after transcatheter closure. 2016 , 12, 1609-1613	5

626	genetic variations associated with COPD risk in the Chinese Han population. 2016 , 11, 2563-2571	11
625	Abstracts from the XV CIPP Meeting. 2016 , 51 Suppl 43, S8-S89	
624	BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling. 2016 , 21, 727-33	27
623	Mitochondria dysfunction: A novel therapeutic target in pathological lung remodeling or bystander?. 2016 , 166, 96-105	23
622	Pulmonary hypertension in patients on chronic hemodialysis and with heart failure. 2016 , 20, 208-17	7
621	Quality of life in patients with chronic thromboembolic pulmonary hypertension. 2016 , 48, 526-37	34
620	Resveratrol prevents pulmonary trunk remodeling but not right ventricular hypertrophy in monocrotaline-induced pulmonary hypertension. 2016 , 23, 243-250	11
619	Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients. 2016 , 95, e4827	14
618	Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol. 2016 , 5, 89	7
617	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. 2016 , 48, 1658-1667	35
616	CT evaluation of small pulmonary vessels area in patients with COPD with severe pulmonary hypertension. 2016 , 71, 830-7	22
615	Biochemistry of Oxidative Stress. 2016 ,	3
614	Feasibility and safety of cardiopulmonary exercise testing in children with pulmonary hypertension. 2016 , 26, 1144-50	8
613	Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study. 2016 , 26, 1250-9	20
612	Composite indices of upstream pulmonary vascular impedance and capacitance do not help in identifying patients who should undergo pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. 2016 , 71, 281-290	
611	Cas clinique n° 4 : une dyspnée chez une patiente atteinte d'une neurofibromatose de type 1 (maladie de Von Recklinghausen). 2016 , 8, 32-35	
610	Oxidative Stress Influence in the Development of Pulmonary Arterial Hypertension. 2016 , 213-226	
609	Pulmonary veno-occlusive disease. 2016 , 47, 1518-34	134

608	Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography in patients with end-stage renal disease on dialysis therapy. 2016 , 28, 101-12	1
607	Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. 2016 , 149, 660-6	7
606	Pulmonary hypertension: prevalence and risk factors. 2016 , 11, 87-89	9
605	[Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts]. 2016 , 147, 306-12	6
604	Panic Disorder. 2016 ,	0
603	Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. 2016 , 55, 564-575	17
602	Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells. 2016 , 159, 111-115	7
601	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. 2016 , 10, 755-66	4
600	The Na ⁺ /H ⁺ exchanger contributes to increased smooth muscle proliferation and migration in a rat model of pulmonary arterial hypertension. 2016 , 4, e12729	14
599	Pulmonary Veno-Occlusive Disease: A Newly Recognized Cause of Severe Pulmonary Hypertension in Dogs. 2016 , 53, 813-22	12
598	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. 2016 , 44, 255-262	0
597	A comparative analysis of global shape analysis methods for the assessment of the human right ventricle. 2016 , 4, 327-343	3
596	Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy. 2016 ,	
595	Operability assessment in CTEPH: Lessons from the CHEST-1 study. 2016 , 152, 669-674.e3	41
594	Relationship of pulmonary arterial pressure and terrain use of Angus cows grazing high-altitude foothill rangelands. 2016 , 190, 76-80	3
593	Assessment for Pulmonary Artery Hypertension Using Clinical and Echocardiographic Criteria in Patients With Systemic Sclerosis. 2016 , 352, 343-347	3
592	Zalecenia dotyczące oceny schorzeń współistniejących u chorych na przewlekłą chorobę płuc w procesie wyboru inhibitora kinaz tyrozynowych. 2016 , 47, 184-196	1
591	The Echocardiographic Assessment of Pulmonary Arterial Hypertension. 2016 , 872-882	

590	Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. 2016 , 311, L560-9	24
589	Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPk. 2016 , 102 Suppl 2, ii49-56	52
588	The Evolving Landscape of Exercise-Induced Pulmonary Hypertension. 2016 , 18, 41	0
587	Association between levels of anti-angiogenic isoform of vascular endothelial growth factor A and pulmonary hypertension. 2016 , 222, 416-420	19
586	Shape of the Pulmonary Artery Doppler-Flow Profile Predicts the Hemodynamics of Pulmonary Hypertension Caused by Left-Sided Heart Disease. 2016 , 39, 150-6	3
585	Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease. 2016 , 34, 443-9	14
584	Group 2 Pulmonary Hypertension: Pulmonary Venous Hypertension: Epidemiology and Pathophysiology. 2016 , 34, 401-11	8
583	Cardiopulmonary Exercise Testing as a Tool for Diagnosing Pulmonary Hypertension in Patients with Dilated Cardiomyopathy. 2016 , 21, 263-71	4
582	Prognostic Value of Right Ventricular Tei Index in Dogs with Myxomatous Mitral Valvular Heart Disease. 2016 , 30, 69-75	23
581	You're the Flight Surgeon. 2016 , 87, 833-5	
580	Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-occlusive Disease. 2016 , 37, 523-34	29
579	Changes in Right Ventricular Dysfunction After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. 2016 , 118, 1081-7	26
578	Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension. 2016 , 48, 1386-1395	16
577	Age dependence of pulmonary artery blood flow measured by 4D flow cardiovascular magnetic resonance: results of a population-based study. 2016 , 18, 31	12
576	Pregnancy in systemic autoimmune diseases: Myths, certainties and doubts. 2016 , 147, 306-312	
575	Pulmonary hypertension in adults with congenital heart disease: First data from Latvian PAH registry. 2016 , 36, e20-e21	2
574	Pathology of Transplantation. 2016 ,	1
573	Pulmonary Artery Acceleration Time Provides a Reliable Estimate of Invasive Pulmonary Hemodynamics in Children. 2016 , 29, 1056-1065	94

572	There is no substitute for experience: Lessons learned from CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase Stimulator Trial-1) for future clinical trial design. 2016 , 152, 675-6	
571	Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. 2016 , 6, 3-14	15
570	Effects of bosentan on peripheral endothelial function in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. 2016 , 6, 168-73	6
569	Pulmonary Hypertension Overlap Syndromes: A Real Entity?. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 379-81	15.1 3
568	Extracorporeal life support in lung and heart-lung transplantation for pulmonary hypertension in adults. 2016 , 30, 1152-8	9
567	Epidemiology of Pulmonary Hypertension in Left Heart Disease. 2016 , 59, 3-10	15
566	Upregulation of MicroRNA-214 Contributes to the Development of Vascular Remodeling in Hypoxia-induced Pulmonary Hypertension Via Targeting CCNL2. 2016 , 6, 24661	21
565	Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. 2016 , 9,	111
564	Echocardiographic correlates of severe pulmonary hypertension in adult patients with ostium secundum atrial septal defect. 2016 , 33, 1891-1896	8
563	Expression and analyses of the HIF-1 pathway in the lungs of humans with pulmonary arterial hypertension. 2016 , 14, 4383-4390	18
562	Pulmonary Hypertension in Heart Failure Patients Presenting at OAUTHC, Ile-Ife, Nigeria. 2016 , 10, 187-193	
561	Pulmonary tumour thrombotic microangiopathy. 2016 , 22, 421-8	39
560	Adhesion Molecules: Master Controllers of the Circulatory System. 2016 , 6, 945-73	31
559	Right Ventricular Longitudinal Strain Is Depressed in a Bovine Model of Pulmonary Hypertension. 2016 , 122, 1280-6	3
558	Association of Apical Longitudinal Rotation with Right Ventricular Performance in Patients with Pulmonary Hypertension: Insights into Overestimation of Tricuspid Annular Plane Systolic Excursion. 2016 , 33, 207-15	20
557	Staged Single Ventricle Palliation and Homozygous Sickle Cell Disease. 2016 , 31, 237-41	1
556	High pulmonary vascular resistance in addition to low right ventricular stroke work index effectively predicts biventricular assist device requirement. 2016 , 19, 44-53	15
555	Pulmonary Hypertension Registry of Kerala (PROKERALA) - Rationale, design and methods. 2016 , 68, 709-715	7

554	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. 2016 , 16, 5	8
553	Diagnostik und konservative Therapie der Trikuspidalklappeninsuffizienz. 2016 , 16, 45-51	5
552	Pneumectomy combined with SU5416 induces severe pulmonary hypertension in rats. 2016 , 310, L1088-97	22
551	Pulmonary hypertension in chronic kidney disease: what could change the fate?. 2016 , 35, 63-4	
550	Hemodynamic predictors of long term survival in end stage cystic fibrosis. 2016 , 202, 221-5	8
549	The linear relationship between systolic pulmonary artery pressure and mean pulmonary artery pressure is maintained regardless of autonomic or rhythm disturbances. 2016 , 17, 33	4
548	CASE 3--2016: Cardiopulmonary Instability Following Single-Lung Transplant. 2016 , 30, 539-47	0
547	The Role of Cardiac Magnetic Resonance Imaging in Pulmonary Hypertension. 2016 , 9, 1	1
546	Acquired Mitochondrial Abnormalities, Including Epigenetic Inhibition of Superoxide Dismutase 2, in Pulmonary Hypertension and Cancer: Therapeutic Implications. 2016 , 903, 29-53	22
545	Increase in caveolae and caveolin-1 expression modulates agonist-induced contraction and store- and receptor-operated Ca(2+) entry in pulmonary arteries of pulmonary hypertensive rats. 2016 , 84, 55-66	14
544	The potential role and limitations of echocardiography in acute respiratory distress syndrome. 2016 , 10, 136-48	22
543	Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. 2016 , 133, 1240-8	167
542	Sex Hormones, Sex, Gender, and Pulmonary Hypertension. 2016 , 105-117	
541	The Management of Supraventricular Tachyarrhythmias in Patients with Pulmonary Arterial Hypertension. 2016 , 25, 442-50	11
540	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. 2016 , 69, 177.e1-177.e62	137
539	Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. 2016 , 310, L249-62	47
538	Persistent Challenges in Pediatric Pulmonary Hypertension. 2016 , 150, 226-36	18
537	Kidney-lung connections in acute and chronic diseases: current perspectives. 2016 , 29, 341-348	17

536	Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. 2016 , 34, 751-70	22
535	L'endartéctomie pulmonaire dans l'hypertension pulmonaire post-embolique. 2016 , 2, 35-56	
534	Gender, Sex Hormones and Respiratory Disease. 2016 ,	5
533	Interfacial Rheological Properties of Contrast Microbubble Targestar P as a Function of Ambient Pressure. 2016 , 42, 1010-7	5
532	Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. 2016 , 21, 285-97	19
531	Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model. 2016 , 579, 23-8	23
530	Echocardiographic Reference Values for Right Atrial Size in Children with and without Atrial Septal Defects or Pulmonary Hypertension. 2016 , 37, 686-95	15
529	Genetic counselling in a national referral centre for pulmonary hypertension. 2016 , 47, 541-52	63
528	Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea. 2016 , 20, 613-9	8
527	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	3455
526	Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient. 2016 , 67, 555-9	21
525	Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. 2016 , 25, 61-6	21
524	The Post-Anesthetic Care of Pediatric Patients With Pulmonary Hypertension. 2016 , 20, 63-73	11
523	Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?. 2016 , 160, 125-9	11
522	Pulmonary Complications of Abdominal Diseases. 2016 , 1639-1652.e4	
521	Effect of hypoxia on TRPV1 and TRPV4 channels in rat pulmonary arterial smooth muscle cells. 2016 , 468, 111-130	39
520	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. 2017 , 151, 468-480	57
519	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. 2017 , 36, 399-406	8

518	Pulmonary arterial hypertension associated with connective tissue disease: Insights from Latvian PAH registry. 2017 , 40, e13-e14	3
517	Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature. 2017 , 174, 497-511	11
516	Diagnostic accuracy of cardiovascular magnetic resonance imaging for assessment of right ventricular morphology and function in pulmonary artery hypertension. 2017 , 66, 477-486	1
515	Clinical Classification. 2017 , 3-11	
514	Animal Models with Pulmonary Hypertension. 2017 , 89-99	
513	In vitro characterization studies of self-microemulsified bosentan systems. 2017 , 43, 989-995	8
512	Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction. 2017 , 56, 497-505	45
511	Pulmonary Hypertension. 2017 , 479-487	
510	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. 2017 , 36, 957-967	138
509	Upregulation of SRF Is Associated With Hypoxic Pulmonary Hypertension by Promoting Viability of Smooth Muscle Cells via Increasing Expression of Bcl-2. 2017 , 118, 2731-2738	12
508	Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. 2017 , 38, 249-262	27
507	Respiratory Complications. 2017 , 1-29	
506	The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension. 2017 , 312, L710-L721	40
505	Drug-induced pulmonary arterial hypertension: a review. 2017 , 22, 289-297	18
504	Autophagy as a double-edged sword in pulmonary epithelial injury: a review and perspective. 2017 , 313, L207-L217	25
503	ACR Appropriateness Criteria Suspected Pulmonary Hypertension. 2017 , 14, S350-S361	13
502	Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension. 2017 , 51, 488-495	3
501	High-risk echocardiographic features predict mortality in pulmonary arterial hypertension. 2017 , 189, 167-176	7

500	Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. 2017 , 70, 915-923	4
499	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. 2017 , 122 Suppl 1, S28-S34	6
498	Impact of pulmonary hypertension on biventricular functions tissue doppler echocardiographic study. 2017 , 66, 137-144	
497	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. 2017 , 10,	18
496	Pulmonary arterial hypertension: Specialists' knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA. 2017 , 7, 372-383	10
495	Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. 2017 , 7, 448-454	5
494	Increased mortality from complications of pulmonary hypertension in patients undergoing transcatheter aortic valve replacement. 2017 , 7, 391-398	3
493	Characteristics of pediatric pulmonary hypertension trials registered on ClinicalTrials.gov. 2017 , 7, 348-360	5
492	Hypoxia induces arginase II expression and increases viable human pulmonary artery smooth muscle cell numbers via AMPK β signaling. 2017 , 312, L568-L578	16
491	Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells. 2017 , 312, L649-L656	7
490	La evoluci3n de la hipertensi3n arterial pulmonar a lo largo de 30 a3os: experiencia de un 3centro de referencia. 2017 , 70, 915-923	19
489	The Evolving Classification of Pulmonary Hypertension. 2017 , 141, 696-703	20
488	Real-world, long-term survival of incident patients with pulmonary arterial hypertension. 2017 , 23, 124-131	7
487	Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase. 2017 , 52, 443-457	13
486	Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity. 2017 , 36, 381-390	21
485	EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. 2017 , 151, 821-828	35
484	Diagnosis and Treatment of Pulmonary Hypertension. 2017 ,	0
483	Pulmonary Hypertension in Adult Congenital Heart Disease. 2017 ,	6

482	Pulmonary Hypertension and Thrombembolism—Long-Term Management and Chronic Oral Anticoagulation. 2017 , 2, 727-741	
481	Differences in right ventricular morphology, not function, indicate the nature of increased afterload in pulmonary hypertensive subjects with normal left ventricular function. 2017 , 34, 1584-1592	10
480	Pulmonary Hypertension: Definition, Classification, and Diagnosis. 2017 , 38, 561-570	5
479	Pulmonary veno-occlusive disease: An important consideration in patients with pulmonary hypertension. 2017 , 132, 203-209	5
478	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. 2017 , 129-143	
477	Con: Preinduction Pulmonary Artery Catheter Placement Is Advisable in Patients With Right Ventricular Dysfunction Secondary to Severe Pulmonary Hypertension. 2017 , 31, 1514-1518	3
476	The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. 2017 , 36, 1047-1059	354
475	Lost in translation. 2017 , 154, 1754-1755	
474	MicroRNAs in right ventricular remodelling. 2017 , 113, 1433-1440	18
473	Pulmonary Hypertension and Interstitial Lung Disease. 2017 ,	
472	Invasive Hemodynamics of Pulmonary Disease and the Right Ventricle. 2017 , 6, 329-343	2
471	Associations of Exercise Tolerance With Hemodynamic Parameters for Pulmonary Arterial Hypertension and for Chronic Thromboembolic Pulmonary Hypertension. 2017 , 37, 341-346	9
470	Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. 2017 , 7, 126-136	29
469	Implication of overexpression of dishevelled-associated activator of morphogenesis 1 (Daam-1) for the pathogenesis of human Idiopathic Pulmonary Arterial Hypertension (IPAH). 2017 , 12, 25	3
468	A complete heart block in a young male: a case report and review of literature of cardiac sarcoidosis. 2017 , 22, 55-64	3
467	Acute Right Ventricle Failure in the Intensive Care Unit: Assessment and Management. 2017 , 33, 61-71	27
466	Paediatric pulmonary hypertension: aetiology, pathophysiology and treatment. 2017 , 27, 50-57	1
465	Cardiac catheterization in children with pulmonary arterial hypertension. 2017 , 59, 3-9	3

464	Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. 2017 , 27, 1980-1991	29
463	A review of pediatric pulmonary hypertension with new guidelines. 2017 , 47, 375-380	5
462	Emerging Metabolic Therapies in Pulmonary Arterial Hypertension. 2017 , 6,	32
461	Guidelines for Perioperative Cardiovascular Evaluation and Management for Noncardiac Surgery (JCS 2014) - Digest Version. 2017 , 81, 245-267	14
460	Pathophysiology of Pulmonary Hypertension. 2017 , 9, i-104	
459	Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. 2017 , 2017, 1430350	39
458	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. 2017 , 17, 216	17
457	Medicina interna perioperatoria - Il paziente chirurgico complesso: il ruolo dell'Internista nell'ospedale snello, a misura del paziente, organizzato per intensit� di cure. 2017 , 5, 1	0
456	Hemodynamic Optimization Strategies in Anesthesia Care for Liver Transplantation. 2017 ,	2
455	Use of computed tomography and automated software for quantitative analysis of the vasculature of patients with pulmonary hypertension. 2017 , 50, 351-358	4
454	Effect of Workforce Diversity on Employee� Job Performance: The Empirical Assessment of Education Sector, Jalalabad, Afghanistan. 2017 , 06,	2
453	Pulmonary hypertension among patients undergoing hemodialysis. 2017 , 6, 122-126	4
452	Improvement after Surgical Closure of Secundum Atrial Septal Defects in Adults. 2017 , 08,	
451	Combined disease with pulmonary arterial hypertension and pulmonary venous hypertension revealed after treatment of heart failure with preserved ejection fraction in a case with primary Sj�gren syndrome. 2018 , 28, 193-196	5
450	Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis. 2018 , 8, 2045893217753357	1
449	The effects of pulmonary hypertension severity on the outcomes of mitral valve replacement for rheumatic mitral stenosis. 2018 , 26, 43-48	1
448	Diagnosis, Treatment, and Management of Orthotopic Liver Transplant Candidates With Portopulmonary Hypertension. 2018 , 26, 169-176	10
447	Secondary pulmonary arterial hypertension: to treat or not to treat?. 2018 , 23, 324-329	1

446	New interventions to treat chronic thromboembolic pulmonary hypertension. 2018 , 104, 1480-1483	9
445	Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. 2018 , 11, e001887	65
444	Hypoxia Upregulates Estrogen Receptor α in Pulmonary Artery Endothelial Cells in a HIF-1 α -Dependent Manner. 2018 , 59, 114-126	21
443	Is pulmonary vascular disease reversible with PPAR γ agonists?. 2018 , 25, e12444	7
442	Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension. 2018 , 114, 551-564	49
441	Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. 2018 , 32, 289-299	48
440	Not a Cinderella story. 2018 , 155, 282-284	
439	Effect of Patent Foramen Ovale in Patients With Pulmonary Hypertension. 2018 , 122, 505-510	5
438	Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. 2018 , 36, 1586-1607	48
437	Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use. 2018 , 15, 693-701	14
436	Bone Morphogenetic Protein-Based Therapeutic Approaches. 2018 , 10,	31
435	The Association of Functional Capacity With Right Atrial Deformation in Patients With Pulmonary Arterial Hypertension: A Study With Two-Dimensional Speckle Tracking. 2018 , 27, 350-358	10
434	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. 2018 , 77, 128-132	17
433	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. 2018 , 37, 647-655	31
432	Drug-Induced Lung Injury. 2018 ,	0
431	Comparison of a computed tomographic pulmonary trunk to aorta diameter ratio with echocardiographic indices of pulmonary hypertension in dogs. 2018 , 59, 18-26	11
430	Diesel exhaust inhalation exposure induces pulmonary arterial hypertension in mice. 2018 , 237, 747-755	15
429	Pulmonary Arterial Hypertension and Pregnancy. 2018 , 03, 139-148	1

428	Malattie croniche da ricercare attivamente e mettere in trattamento nel paziente anziano multimorbido al momento della dimissione da un reparto di Medicina Interna a seguito di un ricovero per insufficienza respiratoria acuta attribuita a riacutizzazione di BPCO. 2018 , 1-97	
427	Assessment of Right Ventricular Function in Pulmonary Hypertension with Multimodality Imaging. 2018 , 26, 189-200	14
426	Vascular Diseases. 2018 , 98-126.e1	1
425	Management of Severe Pulmonary Hypertensive Disease for Surgical and Nonsurgical Procedures. 2018 , 56, e28-e55	3
424	How I manage medical complications of β -thalassemia in adults. 2018 , 132, 1781-1791	37
423	Right Heart Failure-Unrecognized Cause of Cardiorenal Syndrome. 2018 , 29, 1795-1798	7
422	Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. 2018 , 13, e0195092	9
421	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. 2018 , 154, 848-861	23
420	Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct. 2018 , 9, 472	16
419	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. 2018 , 6,	50
418	Pulmonary Hypertension. 2018 , 597-606	
417	Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. 2018 , 10, 56	66
416	JNK2 regulates vascular remodeling in pulmonary hypertension. 2018 , 8, 2045894018778156	0
415	Hypoxic-induction of arginase II requires EGF-mediated EGFR activation in human pulmonary microvascular endothelial cells. 2018 , 6, e13693	4
414	Auto-immune Thyroiditis in an Infant Masquerading as Congenital Nephrotic Syndrome. 2019 , 86, 180-182	1
413	The association of nocturnal hypoxia and an echocardiographic measure of pulmonary hypertension in children with sickle cell disease. 2019 , 85, 506-510	9
412	Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1). 2019 , 2019, 2987461	
411	Pulmonary Hypertension. 2019 , 439-447	

410	Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension. 2019 , 40, 1494-1502	
409	Pulmonary Hypertension as a Primary Presentation for Schistosomiasis, a Case Report of Unusual Presentation. 2019 , 2019,	0
408	Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. 2019 , 19, 573	2
407	Cardiovascular effects of intravenous colforsin in normal and acute respiratory acidosis canine models: A dose-response study. 2019 , 14, e0213414	0
406	Implications of renin-angiotensin-system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. 2019 , 42, 1010-1018	3
405	Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. 2019 , 54,	22
404	Perioperative Management of Pulmonary Endarterectomy-Perspective from the UK National Health Service. 2019 , 33, 3101-3109	2
403	Profound Increase of Lung Airway Resistance in Heart Failure: a Potential Important Contributor for Dyspnea. 2019 , 12, 271-279	1
402	Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD. 2019 , 14, 1099-1108	7
401	Challenges in pulmonary hypertension associated with left heart disease. 2019 , 17, 461-472	1
400	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. 2019 , 9, 2045894019851696	5
399	Right ventricular-vascular coupling ratio in pediatric pulmonary arterial hypertension: A comparison between cardiac magnetic resonance and right heart catheterization measurements. 2019 , 293, 211-217	10
398	Medical Therapy for Heart Failure Associated With Pulmonary Hypertension. 2019 , 124, 1551-1567	24
397	A conditional error function approach for adaptive enrichment designs with continuous endpoints. 2019 , 38, 3105-3122	3
396	Pulmonary Hypertension in Children with Sickle Cell Disease: a Review of the Current Literature. 2019 , 7, 33-44	
395	Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. 2019 , 35, e3159	20
394	Role of BRCA1-associated protein (BRAP) variant in childhood pulmonary arterial hypertension. 2019 , 14, e0211450	2
393	Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement, and Mortality. 2019 , 46, 1103-1108	21

392	Diagnosis and Pathophysiological Mechanisms of Group 3 Hypoxia-Induced Pulmonary Hypertension. 2019 , 21, 16	8
391	New Definition of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. 2019 , 200, 386-388	4
390	Respiratory complications of metabolic disease in the paediatric population: A review of presentation, diagnosis and therapeutic options. 2019 , 32, 55-65	3
389	The feasibility in estimating pulmonary vascular resistance by cardiovascular magnetic resonance in pulmonary hypertension: A systematic review and meta-analysis. 2019 , 114, 137-145	2
388	2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension. 2019 , 118, 1584-1609	11
387	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). 2019 , 83, 842-945	67
386	Tumoral pulmonary hypertension. 2019 , 28,	22
385	Clinical relevance of pulmonary vasculature involvement in sickle cell disease. 2019 , 185, 317-326	6
384	Involvement of immune responses in pulmonary arterial hypertension; lessons from rodent models. 2019 , 35, 22	2
383	High stakes anesthesia: Anesthetic considerations and implications for complete dental extraction in a patient with complex comorbidities. 2019 , 19, 167-173	
382	Management of Pulmonary Arterial Hypertension in the Pediatric Patient. 2019 , 21, 162	7
381	Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty. 2019 , 29, 1565-1573	14
380	Detection of Pediatric Pulmonary Arterial Hypertension by School Electrocardiography Mass Screening. 2019 , 199, 1397-1406	9
379	Pulmonary Hypertension. 2019 , 327-341.e9	
378	Risk Factors for Mitral Valve Surgery: Atrial Fibrillation and Pulmonary Hypertension. 2019 , 23, 57-69	2
377	Quantification of biventricular strain and assessment of ventriculo-ventricular interaction in pulmonary arterial hypertension using exercise cardiac magnetic resonance imaging and myocardial feature tracking. 2019 , 49, 1427-1436	11
376	Integrated bioinformatic analysis reveals YWHAB as a novel diagnostic biomarker for idiopathic pulmonary arterial hypertension. 2019 , 234, 6449-6462	24
375	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. 2019 , 53,	1412

374	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. 2019 , 2045894019837849	1
373	Pulmonary hypertension with a low cardiac index requires a higher PaO level to avoid tissue hypoxia. 2020 , 25, 97-103	3
372	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension. 2020 , 119, 300-309	3
371	Acute hypoxic pulmonary hypertension associated with right heart failure. 2020 , 75, 544-548	2
370	Lung transplantation for pulmonary hypertension with giant pulmonary artery aneurysm. 2020 , 159, 2543-2550	6
369	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. 2020 , 439-462	0
368	Pulmonary Artery Acceleration Time in Young Adulthood and Cardiovascular Outcomes Later in Life: The Coronary Artery Risk Development in Young Adults Study. 2020 , 33, 82-89.e1	0
367	Obstructive sleep apnea and cardiovascular disease, a story of confounders!. 2020 , 24, 1299-1313	19
366	Exercise Pulmonary Hypertension Predicts Clinical Outcomes in Patients With Dyspnea on Effort. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 17-26	15.1 33
365	Clinical features and outcome in 25 dogs with respiratory-associated pulmonary hypertension treated with sildenafil. 2020 , 34, 65-73	8
364	High geographic prevalence of pulmonary artery hypertension: associations with ethnicity, drug use, and altitude. 2020 , 10, 2045894019894534	5
363	Five-year Outcomes of Pulmonary Hypertension With and Without Elevated Left Atrial Pressure in Patients Evaluated for Kidney Transplantation. 2020 , 104, 2113-2119	5
362	Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis. 2020 , 10, 204589402095415	
361	Pulmonary hypertension complicating pregnancy: cardiac remodeling and residual concerns. 2020 , 1-6	1
360	'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension. 2020 , 11,	3
359	Endothelial shear stress enhancements: a potential solution for critically ill Covid-19 patients. 2020 , 19, 91	
358	Autophagy, Unfolded Protein Response and Lung Disease. 2020 , 1, 100003-100003	8
357	Mechanical forces alter endothelin-1 signaling: comparative ovine models of congenital heart disease. 2020 , 10, 2045894020922118	

- 356 Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. **2020**, 10, 2045894020911831 ²
- 355 A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. **2020**, 5, 100055
- 354 Full Issue PDF. **2020**, 13, I-CLXVI
- 353 Two-dimensional speckle tracking echocardiography detected interventricular dyssynchrony predicts exercise capacity and disease severity in pre-capillary pulmonary hypertension. **2020**, 8, 456 ⁰
- 352 Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. **2020**, 10, 2045894020923957 ⁰
- 351 Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. **2020**, 55, ³⁰
- 350 Pulmonary Arterial Hypertension in a Patient with a Portosystemic Shunt: Diagnostic Challenge. **2020**, 4, 93-96 ⁰
- 349 Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease. **2020**, 15, S13-S24 ⁸
- 348 Right ventricle in adulthood: CT and MR assessment. **2020**, 96, 487-494 ⁰
- 347 Risk Factors Associated with Development of Pulmonary Arterial Hypertension and Cor pulmonale in Patients with Chronic Obstructive Pulmonary Disease. **2020**, 15, 289-298
- 346 Cardiac MRI in Pulmonary Hypertension: From Magnet to Bedside. **2020**, 40, 982-1002 ²
- 345 Growth Factor Midkine Aggravates Pulmonary Arterial Hypertension via Surface Nucleolin. **2020**, 10, 10345 ³
- 344 Postpartum Pulmonary Hypertension Masquerading as Submassive Pulmonary Embolism: A Case Report and a Literature Review. **2020**, 2020, 8899562
- 343 Right-to-Left Shunt Through Iatrogenic Atrial Septal Defect After MitraClip Procedure. **2020**, 13, 1544-1553 ³
- 342 Pulmonary hypertension in end-stage renal disease. **2020**, 164, 105905 ⁰
- 341 Impact of Nutrition on Pulmonary Arterial Hypertension. **2020**, 12, ⁹
- 340 Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. **2020**, 13, 1395-1405 ¹⁷
- 339 Mouse Models of Heart Failure with Preserved or Reduced Ejection Fraction. **2020**, 190, 1596-1608 ¹⁰

- 338 Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries. **2012**, 7, 249-259 20
- 337 Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension. **2021**, 26, 92-101 4
- 336 Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension. **2021**, 264, 118709 4
- 335 Pulmonary Manifestations of Endocrine and Metabolic Diseases in Children. **2021**, 68, 81-102
- 334 BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival. **2021**, 21, 125-131
- 333 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. **2021**, 57, 6
- 332 United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. **2021**, 159, 311-327 7
- 331 Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. **2021**, 15, 1753466621995040 0
- 330 Roles of Genetic Predisposition in the Sex Bias of Pulmonary Pathophysiology, as a Function of Estrogens : Sex Matters in the Prevalence of Lung Diseases. **2021**, 1303, 107-127 0
- 329 The Patient Presenting for Liver Transplantation. **2021**, 145-148
- 328 Lung Transplantation for Pulmonary Hypertension. **2021**, 1-12
- 327 Redox Regulation, Oxidative Stress, and Inflammation in Group 3 Pulmonary Hypertension. **2021**, 1303, 209-241 0
- 326 Surgical treatment of congenital heart disease with Eisenmenger syndrome. **2021**, 18, 14-18
- 325 Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. **2021**, 7, 21-38
- 324 The prognostic implications of perioperative endogenous hydrogen sulfide and nitric oxide levels in children with congenital heart disease complicated by pulmonary arterial hypertension. **2021**, 180, 1915-1922 3
- 323 Correlation of Computed Tomography Test Bolus Dynamics and Conventional Computed Tomography Parameters With Pulmonary Vascular Resistance in Patients With Pulmonary Arterial Hypertension. **2021**, 13, e13577
- 322 Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. **2020**, 177, 106241 4
- 321 Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension. **2021**, 14, 113-124 0

320	Outcomes of idiopathic pulmonary arterial hypertension in Japanese children: a retrospective cohort study. 2021 , 36, 1392-1399	0
319	An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. 2021 , 17, 200289	
318	Congenital Heart Disease-Associated Pulmonary Hypertension. 2021 , 42, 9-18	3
317	RETROSPECTIVE COMPUTER-ASSISTED IMAGE ANALYSIS OF DOPPLER ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION PATIENTS. 2021 , 21, 2150016	
316	Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease. 2021 , 107, 54-62	3
315	Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension. 2021 , 13, 2746-2757	
314	A new classification of cardio-oncology syndromes. 2021 , 7, 24	6
313	2020 KSC/KATRD Guideline for the Diagnosis and Treatment of Pulmonary Hypertension: Executive Summary. 2021 ,	0
312	Developing a pulmonary hypertension health passport to improve care: A qualitative study. 1-6	
311	World Pulmonary Hypertension Day: reflections and planning. 2021 , 47, e20210251	0
310	The Relationship of Pleural and Pericardial Effusion With Pulmonary Hemodynamics in Patients With Pulmonary Hypertension. 2021 , 361, 731-735	1
309	Quercetin and metabolic syndrome: A review. 2021 , 35, 5352-5364	20
308	Screening for Pulmonary Hypertension in Systemic Sclerosis-A Primer for Cardio-Rheumatology Clinics. 2021 , 11,	1
307	Treatment of pulmonary arterial hypertension in children. 2021 , 11, 1144-1159	1
306	Pulmonary hypertension in patients with chronic myeloid leukemia. 2021 , 100, e26975	2
305	Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. 2021 , 11, e045165	
304	Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension. 2021 , 12, 712583	1
303	Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension. 2021 , 131,	5

302	Right Ventricular Shape Feature Quantification for Evaluation of Pulmonary Hypertension: Feasibility and Preliminary Associations With Clinical Outcome Submitted for Publication. 2022 , 144,	0
301	Classification of Pulmonary Vascular Disease. 2022 , 560-566	
300	Cardiac - Pulmonary Hypertension, Gastro-Intestinal (GOR, Hepatopulmonary Syndrome), Hematology/Oncology (Infections, Approach to Diagnosis), Neuromuscular (Bulbar, Diaphragm, Intercostal, Spinal). 2022 , 308-320	
299	Pulmonary thromboendarterectomy for pulmonary hypertension linked to thalassemia. 2021 , 9, 1591-1593	
298	Animal Models of PAH and Increased Pulmonary Blood Flow. 2021 , 1-25	
297	Histological and Pathological Diagnosis of Pulmonary Hypertension: Pathological Classification of Pulmonary Vascular Lesions. 2011 , 1413-1423	3
296	Metabolic and Clearance Function at the Pulmonary Microvascular Endothelial Surface in Pulmonary Hypertension. 2011 , 105-115	1
295	Epidemiology of Pediatric Pulmonary Hypertension. 2014 , 2123-2137	2
294	Caveolins and lung function. 2012 , 729, 157-79	33
293	Chronic Liver Disease, Cirrhosis and Complications: Part 2: Hepatic Encephalopathy and Other Systemic Effects. 2014 , 497-516	3
292	Pulmonary Arterial Hypertension and Oxidative Stress. 2014 , 259-325	1
291	Acute Right Ventricular Failure. 2015 , 161-205	2
290	Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. 2020 , 89-108	1
289	A Feasibility Study on Kinematic Feature Extraction from the Human Interventricular Septum toward Hypertension Classification. 2014 , 36-47	2
288	Historical Perspective on the Classification and Nomenclature of Pulmonary Hypertension. 2016 , 3-15	1
287	Pathogenesis of Pulmonary Arterial Hypertension. 2017 , 385-401	0
286	Definition and classification of pulmonary hypertension. 2013 , 218, 3-29	13
285	Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. 2013 , 218, 381-408	10

284	Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application. 2013 , 218, 477-511	7
283	Vasoactive Peptides and the Pathogenesis of Pulmonary Hypertension: Role and Potential Therapeutic Application. 2013 , 477-511	8
282	Pulmonary Hypertension: Pathology. 2013 , 59-75	6
281	Newer Indications for ECMO: Pulmonary Embolism, Pulmonary Hypertension, Septic Shock and Trauma. 2014 , 179-192	2
280	Computational Techniques for Analysis of Shape and Kinematics of Biological Structures. 2013 , 251-269	0
279	Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience. 2013 , 755, 299-305	19
278	Pulmonary Hypertension. 2010 , 1224-1243	1
277	Pulmonary Complications of Abdominal Disease. 2010 , 1982-1998	2
276	Pulmonary Hypertension. 2012 , 1696-1718	5
275	Pulmonary Hypertension in Non-Pulmonary Arterial Hypertension Patients. 2013 , 687-696	1
274	Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome. 2017 , 130, 1272-1279	20
273	Borderline pulmonary hypertension associated with chronic hypercapnia in chronic pulmonary disease. 2019 , 262, 20-25	2
272	Should all patients with pulmonary hypertension undergo HIV serologic testing?. 2011 , 104, 589-92	3
271	Pulmonary hypertension in a patient with hereditary haemorrhagic telangiectasia. 2013 , 2013,	9
270	Pulmonary arterial hypertension associated with neurofibromatosis type 1. 2010 , 2010,	2
269	PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. 2017 , 121, 1136-1139	58
268	Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension. 2017 , 195, 292-301	32
267	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. 2013 , 41, 1324-30	16

266	Epidemiology of pulmonary hypertension in the elderly. 2017 , 14, 11-16	6
265	An Autopsy Case of Pulmonary Capillary Hemangiomatosis with an Electron Microscopy Study. 2019 , 20, 1551-1557	3
264	Natural antioxidant dihydroxybenzyl alcohol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human endothelial cells. 2011 , 17, BR235-41	9
263	Assessment of daily life physical activities in pulmonary arterial hypertension. 2011 , 6, e27993	54
262	Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. 2012 , 7, e38519	35
261	Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. 2013 , 8, e65114	29
260	Fibrinogen AThr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance. 2013 , 8, e69635	25
259	Biventricular remodeling in murine models of right ventricular pressure overload. 2013 , 8, e70802	20
258	Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs. 2013 , 8, e75861	10
257	Single intraperitoneal injection of monocrotaline as a novel large animal model of chronic pulmonary hypertension in Tibet minipigs. 2013 , 8, e78965	8
256	Prevalence and clinical characteristics associated with pulmonary hypertension in African-Americans. 2013 , 8, e84264	31
255	Quantification of tortuosity and fractal dimension of the lung vessels in pulmonary hypertension patients. 2014 , 9, e87515	59
254	Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment. 2014 , 9, e87699	9
253	Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. 2014 , 9, e115219	14
252	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. 2015 , 10, e0130072	41
251	Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. 2015 , 10, e0131940	32
250	Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia. 2015 , 10, e0137539	3
249	Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension. 2015 , 10, e0138384	21

248	Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping. 2017 , 12, e0169238	15
247	Magnetic resonance imaging in pediatric pulmonary hypertension. 2015 , 42, 209-15	4
246	[Current issues in pulmonary hypertension]. 2012 , 153, 603-6	1
245	Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors. 2016 , 9, 474-484	2
244	Group 3 pulmonary hypertension: Challenges and opportunities. 2020 , 2020, e202006	3
243	Pulmonary Venous Hypertension: A Pulmonologist's Perspective. 2011 , 10, 18-23	2
242	Idiopathic and Heritable Pulmonary Hypertension in Children: New Insights into Causes, Evaluation, and Treatment. 2011 , 10, 104-108	1
241	Gender, Sex Hormones, and Pulmonary Arterial Hypertension. 2011 , 10, 160-166	3
240	The Global Challenge of Pulmonary Vascular Diseases and its Forgotten Impact in the Developing World. 2012 , 11, 117-118	2
239	Preoperative Considerations in Patients With Pulmonary Hypertension: Your Patient Needs Surgical Clearance. 2013 , 12, 13-17	1
238	Intraoperative Management of Patients with Pulmonary Hypertension. 2013 , 12, 18-23	5
237	Preoperative Assessment and Management of Liver Transplant Candidates With Portopulmonary Hypertension. 2013 , 12, 60-67	2
236	Perioperative Evaluation and Management of Patients With Portopulmonary Hypertension Aiming for Orthotopic Liver Transplantation. 2013 , 12, 68-74	0
235	Classification of Pulmonary Hypertension. 2014 , 13, 17-20	1
234	Pulmonary Hypertension Associated With Sarcoidosis. 2009 , 8, 148-153	2
233	Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review. 2020 , 26, 3862-3870	3
232	Pulmonary hypertension: types and treatments. 2015 , 11, 73-9	22
231	High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management. 2016 , 10, 19-27	33

230	Lack of CTGF*-945C/G Dimorphism in Thai Patients with Systemic Sclerosis. 2011 , 5, 59-63	13
229	Mortality from pulmonary heart disease in Japan, 1979-2006. 2010 , 3, 209-14	1
228	Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy. 2017 , 5, 206-219	1
227	Pediatric lung transplantation: indications and outcomes. 2014 , 6, 1024-31	35
226	Pulmonary hypertension in end-stage renal disease and post renal transplantation patients. 2014 , 6, 606-16	12
225	Pharmacological Management of Pulmonary Arterial Hypertension. 2014 , 25, 309-316	2
224	Sildenafil in pediatric pulmonary arterial hypertension. 2015 , 61, 181-92	16
223	Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial. 2017 , 61, 798-802	2
222	The Right Heart in Congenital Heart Disease, Mechanisms and Recent Advances. 2012 , 8, 1-11	14
221	Transoesophageal echocardiography during liver transplantation. 2015 , 7, 2432-48	23
220	Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. 2020 , 55, 77-84	2
219	Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary arterial hypertension. 2010 , 21, 334-7	9
218	Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. 2018 , 29, 208-212	9
217	Pulmonary Manifestations in Systemic Sclerosis: Hospital-Based Descriptive Study. 2020 , 12, e8649	1
216	Case 1-2021: A 10-Year-Old Male With Respiratory Failure, Pleural Effusions, and Renal Failure 60 Days After Hematopoietic Stem Cell Transplant. 2021 , 22, e524-e531	0
215	Effects of different anesthesia methods on maternal and neonatal outcomes in pregnant patients with pulmonary arterial hypertension: a meta-analysis. 2021 , 1	
214	Pulmonary Hypertension in Obstructive Sleep Apnea Syndrome. 2009 , 8, 131-140	
213	Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis. 2009 , 8, 141-147	

212 Cor Pulmonale. **2010**, 1326-1355

211 Assessment of Pulmonary Vascular Disease. **2010**, 223-230

210 Utilisation de l'Extra corporeal membrane ox ygenation (ECMO) dans l'Émbolie pulmonaire et l'Hypertension artfielle pulmonaire. **2010**, 199-211

209 What is the Impact of Obesity in PH?. **2010**, 9, 120-120

208 Update From the NHLBI on Lung Vascular and Pulmonary Hypertension Research. **2010**, 9, 152-155

207 Classification of Pulmonary Hypertension: History and Perspectives. **2011**, 937-942

206 Cardiac Catheterization in the Patient with Pulmonary Hypertension. **2011**, 1387-1402

1

205 Epidemiology of Pulmonary Arterial Hypertension. **2011**, 943-961

204 Ask the Expert. **2010**, 8, 197-236

203 Genomic Applications to Study Pulmonary Hypertension. **2011**, 581-590

202 Late Limited Systemic Sclerosis Patient Who Develops Shortness of Breath on Exertion. **2011**, 127-137

201 Pulmonale Hypertonie. **2011**, 309-334

200 Systemic Sclerosis: Severe Involvement of Internal Organs. **2011**, 67-88

199 Pulmonary management of systemic sclerosis. **2011**, 1413-1425.e1

198 Gene therapy for pulmonary arterial hypertension: is a cure in sight?. **2011**, 11, 129-31

197 Leitsymptom Dyspnoe, Leistungsschwäche. **2011**, 87-194

196 Anesthesia for Patients with End-Stage Lung Disease. **2011**, 343-365

195 Carboxyhemoglobin formation secondary to nitric oxide therapy in the setting of interstitial lung disease and pulmonary hypertension. **2011**, 104, 46-8

1

194 Pulmonale Hypertonie (PAH) und akute Rechtsherzdekompensation. **2011**, 465-473

193 Pulmonary veno-occlusive disease. **2011**, 435-446

192 Pulmonary hypertension secondary to left heart failure. **2011**, 425-434

191 Pulmonary hypertension related to appetite suppressants. **2011**, 236-244

190 The image of pulmonary hypertension. **2011**, 37, 283-4

1

189 Pulmonary Hypertension. **2012**, 169-186

188 Pulmonary Hypertension in Older Patients. **2012**, 111-131

187 Inflammation in Pulmonary Arterial Hypertension. **2012**, 213-229

1

186 Understanding the Pathobiology of Pulmonary Vascular Disease. **2012**, 203-212

185 Pulmonary Hypertension. **2012**, 213-223

184 Pulmonary Hypertension in Interstitial Lung Disease. **2012**, 121-135

183 Molecular Genetics of Pulmonary Hypertension.

182 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80

181 2. Guanylate Cyclase Enhancer. **2012**, 43, 311-315

180 A Case of Adenocarcinoma of the Lung Complicated with Chronic Thromboembolic Pulmonary Hypertension That Underwent Upper Pulmonary Lobectomy. **2012**, 52, 1023-1029

179 Pulmonary Hypertension/Eisenmenger Syndrome. **2012**, 2413-2423

178 Pulmonary Arterial Hypertension: Psychosocial Implications and Treatment. 88-98

177 A Case of Idiopathic Pulmonary Arterial Hypertension with a BMPR2 Mutation. **2012**, 83, 238

176 Krankheiten des Herzens. **2012**, 335-393

175 ?????????????(??????). **2012**, 20, 21-28

174 Helping Patients Understand the Complex Pulmonary Hypertension Workup. **2012**, 11, 65-66

173 Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (Including Eisenmenger Syndrome). 168-175

172 Disability in Pulmonary Hypertension. **2012**, 10, 241-243

1

171 Pulmonary Hypertension. **2013**, 759-763

170 Pulmonary Hypertension in Neurofibromatosis Type 1: A Case Report. **2013**, 85, 521

169 ECG P wave abnormalities. **2013**, 54, 4-7; quiz p.7

168 Pulmonary Hypertension. **2014**, 97-114

167 Targeted therapies: prostaglandins. **2013**, 52-63

166 Index. **2013**, 122-123

165 Surgical approaches in pulmonary arterial hypertension. **2013**, 88-97

164 Monitoring and prognosis of pulmonary arterial hypertension. **2013**, 98-111

163 Etiology and prevalence of pulmonary arterial hypertension. **2013**, 6-22

162 Echocardiography in the ICU. **2014**, 879-899

161 Instructive Cases of Pulmonary Sarcoidosis. **2014**, 187-213

160 Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. **2014**, 2139-2158

159 Pathology, Pathobiology and Pathophysiology of Pulmonary Arterial Hypertension. **2014**, 2081-2101

158 Recognizing and Treating Comorbidities of IPF. **2014**, 313-336

157 Sarcoidosis-Associated Pulmonary Hypertension. **2014**, 111-128

156 Animal Models for PAH and Increased Pulmonary Blood Flow. **2014**, 2103-2121

155 Anesthetic Techniques for Specific Cardiac Pathology. **2014**, 625-657

154 Pulmonary hypertension in scleroderma and its relation to disease activity. **2013**, 40, 173-180

1

153 Heart Failure and Pulmonary Hypertension in Women. **2014**, 155-173

152 Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. **2013**, 11, 183-188

151 Self-Similarities of Pulmonary Arterial Tree and a New Integrated Model of Pulmonary Circulation with the Name of Fractal Phasic Perfusion (FPP) Model. **2014**, 05, 1801-1809

150 Persistent Pulmonary Hypertension of the Newborn. **2014**, 1-27

149 Pulmonary Venous Hypertension. **2014**, 1-14

148 Hemoptysis after percutaneous transluminal angioplasty for left stenotic brachiocephalic vein in a patient on maintenance hemodialysis. **2014**, 47, 329-333

147 Chapter 13:Treatments for Pulmonary Arterial Hypertension. **2014**, 369-397

146 Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. **2014**,

145 Aging and Right Ventricular Failure from Pulmonary Hypertension: Effect of Right Ventricular and Pulmonary Artery Remodeling. **2014**, 291-304

144 Experimental Models. **2014**, 45-67

143 Acute heart failure. **2014**, 271-288.e5

142 Pulmonary Arterial Hypertension in Intensive Care Unit. **2014**, 37-58

141 Comprehensive Medical Evaluation. **2014**, 35-50

140 Pulmonale Hypertonie (PAH) und akute Rechtsherzdekompensation. **2014**, 497-505

139 Beta-Blockers for All Ibr Not. **2014**, 63-73

1

138 Vascular Genetics. **2014**, 1-41

137 Leitsymptom Dyspnoe, Leistungsschwäche. **2014**, 111-222

136 Contraceptive Management of Women with Cardiac Disease. **2014**, 17-39

135 Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database. **2013**, 1, 254-265

1

134 Pulmonary hypertension in idiopathic pulmonary fibrosis. **2014**, 8, 23-31

133 Nitric Oxide and Pulmonary Vasodilators. **2015**, 275-293

132 Pulmonary Hypertension in Orphan Lung Diseases. **2015**, 529-539

131 Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia. **2015**, 191-200

0

130 Pulmonary Pressure as a Novel Prognostic Biomarker in Renal Patients. **2015**, 1-21

129 Surgical Treatment for Chronic Pulmonary Thromboembolism with Bronchial Artery-Pulmonary Artery Fistula. **2015**, 26, 251-255

128 Encyclopedia of Trauma Care. **2015**, 1365-1371

127 Combination Therapy for the Treatment of Pulmonary Arterial Hypertension. **2015**, 377-396

126 Pathogenesis of Pulmonary Arterial Hypertension. **2015**, 37-65

125 Hypoxic Pulmonary Hypertension. **2015**, 67-92

124 A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension. **2015**, 10, 102-107

123 Fibrocytes and Pulmonary Vascular Remodeling: The Good, the Bad, and the Progenitors. **2015**, 257-276

122 Pulmonary Venous Hypertension. **2015**, 4157-4168

121 Vascular Genetics. **2015**, 53-88

120 Pulmonary management of systemic sclerosis. **2015**, 1200-1212

119 Persistent Pulmonary Hypertension of the Newborn. **2015**, 4135-4155

118 Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. **2015**, 14, 138-144

o

117 Pulmonary Hypertension Associated with Respiratory Disease. **2015**, 4211-4231

116 A PROSPECTIVE STUDY OF PULMONARY ARTERIAL HYPERTENSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASES. **2015**, 2, 2379-2383

115 Ambulatory Hemodynamic Monitoring of Pulmonary Hypertension. **2015**, 16, 154-164

114 Correlation between Automated Quantification of Lung Perfusion Blood Volume (PBV) and Pulmonary Artery Pressure. **2016**, 06, 105-112

o

113 Parasitic Diseases of the Lung. **2016**, 231-253

112 The benefit of using a low dose calcium channel blocker in a patient with idiopathic pulmonary hypertension. **2016**, 35, 60-64

111 Pulmonary and Airway Emergencies. **2016**, 93-111

110 Pulmonary Pressure as a Novel Prognostic Biomarker in Renal Patients. **2016**, 1121-1141

109 Right Ventricular Metabolism and Its Efficiency. **2016**, 193-207

1

108 Tuberculosis and pulmonary hypertension: Commentary. **2016**, 33, 232-3

2

107 Lung Transplantation. **2016**, 121-172

106 The Cardiopulmonary Hemodynamic Evaluation of Pulmonary Hypertension. **2016**, 173-198

105 Pulmonary Embolism in the Setting of Panic Attacks. **2016**, 211-216

104 World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease. **2016**, 440-455

103 Role of mean platelet volume in patients with chronic obstructive pulmonary disease. **2016**, 10, 251-260

102 Hoarseness of voice as presenting complaint of idiopathic pulmonary arterial hypertension. **2017**, 34, 212-214

o

101 Three Element Windkessel Model to Non-Invasively Assess PAH Patients: One Year Follow-up. **2017**, 151-154

100 Systemic and Pulmonary Hypertension in Obstructive Sleep Apnea. **2017**, 1253-1263.e4

99 Acute Right Heart Failure. **2017**, 209-271

98 Pulmonary Hypertension in Left Heart Disease. **2017**, 341-369

97 PAH in Patients with Prevalent Systemic Pulmonary Shunts and PAH in Patients with Small Cardiac Defects. **2017**, 45-60

1

96 Pulmonary Vascular Disorders. **2017**, 137-156

95 Reversible pulmonary hypertension in post-renal transplantation patient with longstanding arteriovenous fistula. **2017**, 19, 57-62

94 Therapeutic Strategies for DLI: How Should DLI Be Treated?. **2018**, 115-125

93 DLI Induced by Herbal Medicine: What Are the Characteristics of DLI due to Herbal Medicines?. **2018**, 177-199

92 Prevalence of Pulmonary Arterial Hypertension on Echocardiography in Newborns with Maternal Risk factors. **2017**, 3,

91 Correlation between mean pulmonary arterial pressure measurement by echocardiography and right ventricular function. **2018**, 6, 11

90 Cardiac Manifestations of Cancer and Their Management. **2018**, 181-197

89 Pulmonary Pathology. **2018**, 359-363

88 Cardiopulmonary Complications of Cirrhosis. **2018**, 281-292.e5

87 AN EPIDEMIOLOGICAL STUDY OF PULMONARY HYPERTENSION BY ECHOCARDIOGRAPHY IN TERTIARY CARE INSTITUTE, TAMILNADU, SOUTH INDIA. **2018**, 7, 3950-3953

- 86 Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan. **2020**, 27, 100-102 1
- 85 Cardiovascular effects of intravenous colforsin in normal and acute respiratory acidosis canine models: a dose-response study.
- 84 A CLINICO-ETIOLOGICAL STUDY OF PULMONARY HYPERTENSION IN ADULTS IN A RURAL TERTIARY CARE HOSPITAL. **2019**, 8, 685-688
- 83 Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension - Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE). **2019**, 1, 303-311 1
- 82 Prevalence of Pulmonary Hypertension in COPD Patients. **2019**, 6, 2742-2745
- 81 Association of Pulmonary Hypertension With End-Stage Renal Disease Among the Obese Population. **2020**, 12, e9722
- 80 Application of 7.0 T ultra-high-field MRI in evaluating the structure and function of the right ventricle of the heart in rats under a chronic hypoxic environment at high altitude. **2021**, 9, 1585 1
- 79 Pulmonary manifestations of chronic liver disease: a comprehensive review. **2020**, 33, 237-249 5
- 78 When the body is defective: An object relations informed narrative analysis of the illness experience of people affected by pulmonary hypertension. **2020**, 817-834
- 77 Mesenchymal Tumors of the Lung. **2020**, 435-539
- 76 Epidemiology of Pediatric Pulmonary Hypertension. **2020**, 1-17
- 75 Group III Pulmonary Hypertension: relative frequency of different etiologies in a referral pulmonary OPD. **2020**, 8, 69
- 74 Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. **2020**, 123-134 1
- 73 Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension. **2020**, 147-171
- 72 Pulmonary hypertension - prevalence, risk factors, and its association with vascular calcification in chronic kidney disease and hemodialysis patients. **2020**, 31, 380-387 2
- 71 Pulmonary Hypertension in Chronic Kidney Disease and End-Stage Renal Disease. **2020**, 173-194 1
- 70 Pulmonary Vascular Disease Evaluation with Magnetic Resonance Angiography. **2020**, 58, 707-719 0
- 69 Contraceptive Management of Women with Cardiac Disease. **2014**, 17-39 0

68	Anti-inflammatory and immunosuppressive agents in PAH. 2013 , 218, 437-76	12
67	Pulmonary hypertension: pathology. 2013 , 218, 59-75	2
66	Computed axial tomography evidence of left atrial enlargement: a predictor of elevated pulmonary capillary wedge pressure in pulmonary hypertension. 2010 , 3, 23-9	6
65	Prostacyclin therapy for pulmonary arterial hypertension. 2010 , 37, 391-9	32
64	Management and Controversies in Pediatric Pulmonary Hypertension. 2009 , 22, 139-150	1
63	Associated pulmonary arterial hypertension in connective tissue diseases. 2011 , 6, 141-5	3
62	Platelets in pulmonary hypertension: a causative role or a simple association?. 2012 , 22, 145-57	13
61	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. 2010 , 26, 206-218	1
60	New Echocardiographic Tehniques in Pulmonary Arterial Hypertension vs. Right Heart Catheterization - A Pilot Study. 2013 , 8, 116-23	5
59	Prevalence and Characteristics of Pulmonary Hypertension Associated with COPD - A Pilot Study in Patients Referred to a Pulmonary Rehabilitation Program Clinic. 2013 , 8, 243-8	6
58	Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sildenafil. 2014 , 6, 1411-9	1
57	Complete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case report. 2014 , 9, 198-203	1
56	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. 2015 , 67, 169-85	5
55	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. 2014 , 30, 401-44	11
54	Role of Meticulous Observation: Successful Pregnancy in a 30-Year-Old Woman with Severe Pulmonary Hypertension. 2016 , 15, 187-190	0
53	Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan. 2017 , 33, 498-509	11
52	Study of Pulmonary Hypertension in Patients Suffering from Chronic Obstructive Pulmonary Disease. 2016 , 42, 157-163	
51	Chronic thromboembolic pulmonary hypertension - still evolving. 2020 , 2020, e202011	1

50 Pulmonary Hypertension. **2022**, 40, xi-xii

49 Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. **2021**, 21, 365

48 Functional Disability Among Systemic Sclerosis Patients: Relation to Disease Characteristics and Quality of Life Parameters. **2021**,

47 Health-related quality of life and parental depression in children with pulmonary arterial hypertension. **2021**,

46 Chronic thromboembolic pulmonary hypertension is still evolving. **2020**, 2020, e202011

45 Pulmonary Hypertension. **2022**, 538-546

44 Cardiovascular effects of intravenous pimobendan in dogs with acute respiratory acidosis.. **2022**,

43 The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1 α /XBP1s pathway. **2022**,

42 Physical activity and its clinical correlates in chronic thromboembolic pulmonary hypertension.. **2022**, 12, e12048

41 The impact of sex chromosomes in the sexual dimorphism of pulmonary arterial hypertension.. **2022**,

40 The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension. **2022**, 2022, 1-10

39 A review of genetically-driven rodent models of pulmonary hypertension.. **2022**, 144, 106970

38 Pulmonary Hypertension in Chronic Hemodialysis Patients at Aristide Le Dantec University Hospital. **2022**, 12, 93-100

37 Clinical characteristics associated with small airways disease in systemic sclerosis.. **2022**, 7, 128-134

36 Prostacyclin for Pulmonary Arterial Hypertension. **2022**, 42, 79-81

35 The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.. **2022**, 196, 106801

34 Risk Factors of Pulmonary Hypertension in Patients on Hemodialysis: A Single Center Study.. **2021**, 14, 487-494

33 Non-neoplastic lung diseases. 1204-1334

- 32 Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.. **2022**, 38, 113-123
- 31 Hipertens  pulmonar na esclerose sist mica. **2014**, 24-27
- 30 Classifica  da hipertens  pulmonar. **2014**, 6-15
- 29 Cor pulmonale (akut und chronisch) [Begutachtung. **2022**, 1-7
- 28 Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. **2022**, 9, 151-160 1
- 27 Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis. **2022**, 9,
- 26 Coexistent Chronic Obstructive Pulmonary Disease-Heart Failure: Mechanisms, Diagnostic and Therapeutic Dilemmas. **2022**, 52, 225-238 0
- 25 Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. **2022**, 52, 29-40 1
- 24 Of Registries and Disease Classification: Unmasking the Challenges of Pediatric Pulmonary Hypertension.
- 23 Manifestations of Pulmonary Disease in Adults with Congenital Heart Disease. **2022**, 55, 85-95
- 22 Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NF  inactivation. **2022**, 23, 1
- 21 Severe Right Heart Failure in a Patient with Chronic Obstructive Lung Disease: A Diagnostic Challenge. **2022**, 55, 159-162
- 20 AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM. **2014**, 95-108
- 19 Role of solid lipid nanoparticle for the delivery of Lipophilic Drugs and Herbal Medicines in the treatment of pulmonary hypertension. **2022**, 10, 0
- 18 Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. 13, 1
- 17 Respiratory Complications. 1-37 0
- 16 Pulmonary Veno-Occlusive Disease Versus Pulmonary Arterial Hypertension. **2022**, 345-348 0
- 15 Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance. **2022**, 2022, 1-8 0

- 14 Schistosomiasis-Associated Pulmonary Arterial Hypertension. **2022**, 21, 109-114 ○
- 13 ACR Appropriateness Criteria[®] Suspected Pulmonary Hypertension: 2022 Update. **2022**, 19, S502-S512 ○
- 12 The Role of Bone Morphogenetic Protein Receptor Type 2 (BMP2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. **2022**, 11, 3823 ○
- 11 Predictors of Post-induction Hypotension for Patients With Pulmonary Hypertension. **2022**, ○
- 10 Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design. **2022**, 23, ○
- 9 Imaging the right atrium in pulmonary hypertension: a systematic review and meta-analysis. **2022**, ○
- 8 Invasive Exercise Hemodynamics: An Oracle in Heart Failure with Preserved Ejection Fraction Diagnosis and Prognostication. ○
- 7 Diagnostic accuracy and predictive value of autoantibody profiles in patients with systemic sclerosis: a single-center study. ○
- 6 Pediatric Population Pharmacokinetic Modeling and Exposure-response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison with Adult Data. ○
- 5 The percentage of circulating fibrocytes is associated with increased morbidity of pulmonary hypertension in patients on hemodialysis. ○
- 4 Study of Respiratory Variations of Mitral Valve Diastolic Flow in Hemodialysis Patients. 000331972311555 ○
- 3 Current clinical understanding and effectiveness of portopulmonary hypertension treatment. 10, ○
- 2 Pulmoner arteriyel hipertansiyonlu hastalarda vagal-nöroimmünomodülasyon endeksinin rolü. **2023**, 4, 94-97 ○
- 1 Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension. 1-16 ○